VOLUME 8 1987

SUBJECT INDEX

A-18-F-NH_2, 657
  brain, bovine
  F-8-F-NH_2
  opioid antagonist characterization
  opioid antagonist distribution
  radioimmunoassay
Acetorphan, 89
  cats
  enkephalins
  gastric secretion
N-Acetylated endorphins, 1045
  anterior pituitary
  neurointermediate lobe
  sheep pituitary
ACTH secretion, 113
  corticosterone secretion
  CRF release
  (D-Ala^2,Met^5)-enkephalinamide (DALA)
Activity, 1135
  alcohol
  cardiovascular responses
  dependence
  drinking
  eating
  endogenous opiates, review
  epilepsy
  immune system
  learning
  memory
  mental illness
  respiration
  schizophrenia
  sex
  social behavior
  stress
  stroke
  temperature
  tolerance
Adrenal medulla, 437
  corticotropin-releasing factor
  dopamine beta-hydroxylase
  phenethanol N-methyltransferase
  plasma corticosterone
  route of administration
Adrenergic neurons, 145
  gastrointestinal tract
  immunoreactivity
  neuropeptide Y
Adrenocorticotropic hormone
  cocaine, 819
  corticosterone, 819
  corticotropin-releasing factor, 841
  corticotropin releasing factor-like immunoreactivity, 819
  β-endorphin, 819
  grooming, 841
  hypothalamus, 819
  rat/mice comparisons, 841
Age differences, 231
  hypertension
  receptor distribution
  strain differences
  thyrotropin-releasing hormone
Aggregation, 599
  degradation
  delta sleep-inducing peptide
  delta sleep-inducing peptide analogues
  plasma, human
  plasma, rat
Aggression, 935
  corticotropin releasing factor
  isolation
  sauvagine
  social behavior
Alcohol, 1135
  activity
  cardiovascular responses
  dependence
  drinking
  eating
  endogenous opiates, review
  epilepsy
  immune system
  learning
  memory
  mental illness
  respiration
  schizophrenia
  sex
  social behavior
  stress
  stroke
  temperature
  tolerance
Alzheimer's disease, 593
  cerebrospinal fluid
  human plasma
  pituitary protein
γ-Aminobutyric acid
  benzodiazepine receptor binding
  MIF-1
  Tyr-MIF-1
Aminopeptidase M, 523
  blood vessels
  enkephalin metabolism
  immunohistochemistry
  localization, enzyme
  localization, peptide
  pituitary
Aminosuccinyl residue identification, 791
  ultraviolet spectrometry
Aminoterminal CNBr fragments, 773
  catalytic activity
  lactate dehydrogenase isoenzymes
  reactivation agonists
  reversed-phase HPLC
  quaternary structure
Amnesia, 605
  electroconvulsive shock
  β-endorphin
  memory disruption
Amphibians, 61
  melanophore-stimulating hormone
  neuropeptide Y
  secretion regulation
Amygdala, 159
  brain, monkey
  hypothalamus
  immunoreactive levels
  neuropeptide Y
Analgesia
  brain Met-enkephalin content, 355
  diuresis, 811
  dynorphin, 191
  dynorphin analog, 811
  human studies, cancer patients, 191
  intestinal transit, 613
  intrathecal administration, 191
  kentsin, 613
  opioid receptors, 613
  pain, 191
  receptor selectivity, 811
  stress, 355
Analgesia, non-opioid, 905
  GABA release
  neo-kyotorphin
Angina pectoris, 285
  atrial natriuretic factor
  atrial natriuretic polypeptide
  cardiac output
  hemodynamic variables
  human studies
  pulmonary arterial pressure
Angiotensin I, 939
  angiotensin II
  cerebrospinal fluid
  dogs
  high performance liquid chromatography
  plasma
Angiotensin II, 939
  angiotensin I
  cerebrospinal fluid
  dogs
  high performance liquid chromatography
  plasma
Angiotensin II binding, 737
  autoradiography
  spleen
Angiotensin receptors, 677
  brainstem binding sites
  nodose ganglionectomy
Anorexia, 237
  bombesin
  feeding behavior
  hypothalamus
Anorexia, tumor-induced, 223
  behavioral tolerance
  cholecystokinin
  eating
Anterior pituitary
  N-acetylated endorphins, 1045
  cyclic AMP, 199
  desensitization, 199
  dynorphin-A, 367
  17β-estradiol, 367
  gonadotropin releasing hormone, 543
  gonadotropin secretion, 539
  growth hormone, 199
  growth hormone-releasing factor, 199
  immunoreactivity, 367, 543
  in vitro, 367
  in vivo, 367
  long-term primary cultures, 543
  molecular weight, 367
  neurointermediate lobe, 1045
  neuropeptide Y, 539
  pancreatic polypeptide, 539
  peptide distribution, 543

peptide release, 367
rats, males, 539
sheep, 367
sheep pituitary, 1045
somatostatin, 199
thyrotropin releasing hormone, 543
Anterior pituitary, bovine, 361
dynorphin-A
immunoreactivity
in vitro
molecular weight
peptide release
Antiserum specificity, 135
fishes, bony
hypothalamus
immunoreactivity
neurotensin
pituitary
Aplysia, 179
peptide sequencing
precursor processing
purification
small cardioactive peptide A
[^{3}H]Apomorphine binding, 319
dopamine receptors
in vitro
receptor modulation
receptor-receptor interaction
[^{3}H]spiperone binding
thyrotropin-releasing hormone
Arginine vasopressin
body temperature, 385
brain, rabbit, 385
desglycinamide vasopressin, 785
exploratory activity, 785
fever, 385
memory retrieval, 493
novel environment, 785
prenatal administration, 493
septum, 385
sexual dimorphism, 493
vasopressin antiserum, 385
Arterial pressure, 887
bombesin
gastric motility
nucleus tractus solitarius
Arteries, rat/bovine comparisons, 477
coronary artery
mesenteric artery
radioligand binding study
vasoactive intestinal receptors
Arteriolar dilation, 443
in vivo
muscarinic receptor stimulation
parathyroid hormone fragments
ATPase activity inhibition, 709
cardiac sarcolemma
drug interactions
morphine
opioid peptides
Atrial natriuretic factor
angina pectoris, 285
atrial natriuretic polypeptide, 285
biological activity, 461
cardiac output, 285
hemodynamic variables, 285
human studies, 285
hypothalamic action, 449
immunoreactivity, 461
posterior hypophysis, 461
pulmonary arterial pressure, 285
vasopressin secretion, 449
Atrial natriuretic peptide
in situ retrograde perfused heart
right atrial pressure
vagotomy, bilateral
volume expansion
Atrial natriuretic polypeptide, 285
angina pectoris
atrial natriuretic factor
cardiac output
hemodynamic variables
human studies
pulmonary arterial pressure
Autoradiography
angiotensin II binding, 737
binding sites, 391
chief cells, 391
[^{125}I]FK33824, 1015
gastric mucosa, 391
^{125}I-iodotyrosyl gastrin I, 391
mu opioid binding sites, 1015
parietal cells, 391
spleen, 737
Avian feeding patterns, 585
chicks
narcolepsy
neonatal exposure
pancreatic polypeptides
tonic-clonic convulsions
Avidin-biotin-peroxidase complex, 569
brain, cats
hypothalamus
immunoreactivity
localization
neuropeptide Y
Avidin-biotin peroxidase complex
modification, 327
cats
central nervous system
immunoreactivity
α-melanocyte stimulating hormone

Background adaptation, 69
brain, toads
melanophore stimulating hormone
melanophore stimulating hormone release
pars intermedia
thyrotropin releasing hormone
Bag cell neurons, 829
density gradient
neuropeptides
neurosecretory granules
Basal conditions, 291
in vitro release
regional distribution
stimulated conditions
thyrotropin-releasing hormone
Behavioral tolerance, 223
anorexia, tumor-induced
cholecystokinin
eating
Benzodiazepine receptor binding, 751
γ-aminobutyric acid
MIF-1
Tyr-MIF-1
Binding sites
autoradiography, 391
chief cells, 391
gastric mucosa, 391
human fetus, 947
^{125}I-iodotyrosyl gastrin I, 391
parietal cells, 391
substance P, 947
Biological activity, 461
atrial natriuretic factor
immunoreactivity
posterior hypophysis
Biological potency, 877
epidermal growth factor
mitogenesis
N-terminal heterogenecity
receptor binding
Blood-brain barrier
central nervous system, 261
cerebrospinal fluid, 261
desglycinamide-arginine-vasopressin, 261
human studies, 261
methionine enkephalin, 899
transport system, 899
Tyr-MIF-1, 899
Blood pressure, 227
body temperature
hypertension
hyperthermia
rats, spontaneously hypertensive
supersensitivity
thyrotropin releasing hormone
Blood vessels, 523
aminopeptidase M
enkephalin metabolism
immunohistochemistry
localization, enzyme
localization, peptide
pituitary
Body temperature
arginine vasopressin, 385
blood pressure, 227
brain, rabbit, 385
enkephalin dimers, 431
fever, 385
hypertension, 227
hyperthermia, 227
hypothermia, 431
rats, spontaneously hypertensive, 227
septum, 385
supersensitivity, 227
thyrotropin releasing hormone, 227
vasopressin antiserum, 385
Body weight, 455
ceruletide
double-blind study
food intake
human studies, obese females
hunger
obesity
Bombesin
anorexia, 237
arterial pressure, 887
dogs, 973
feeding behavior, 237
gastric motility, 887
hypothalamus, 237
nucleus tractus solitarius, 887
pancreatic exocrine secretion, 973
pancreatic polypeptide-antiserum, 973
Bradykinin, 863
dose-dependent effects
epicardial application
guinea pigs
pressor effects
tachycardia
Brain
adrenal medulla, 77

Ammon's horn, 911
amygdala, 159, 291, 237
amygdaloid nucleus, 355
anterior hypothalamus, 237
anterior pituitary, 35, 199, 361, 367, 543, 1045
area postrema, 677
brainstem, 1173
caudate nucleus, 837
cerebellum, 657, 947
cortex, 231, 657, 1075
dentate gyrus, 911
diagonal band of Broca, 721
dorsal motor nucleus of the vagus, 677
dorsal thalamus, 1015
dorsal vagal motor nucleus, 505
dorsomedial nucleus, 237
entorhinal cortex, 911
extrahypothalamic, 185
forebrain, 335
fourth ventricle, 237
frontal cortex, 947
hilus, 911
hippocampus, 355
hippocampus, human, 911
hypothalamic arcuate nucleus, 371
hypothalamic ventromedial nucleus, 371
hypothalamus, 21, 45, 61, 135, 185, 231, 291, 327, 355, 449, 505, 543, 569, 721, 819, 1015, 1035
infundibular nucleus, 327
intermediate lobe, 61
lateral hypothalamus, 237, 327
lateral septum, 291
lamina terminalis, 335
limbic forebrain, 319
locus ceruleus, 327
medial basal hypothalamus, 35, 327, 335
medial eminence, 371
medial nucleus, 327
medial septum, 335
medial subnucleus of the nucleus tractus solitarius, 887
median eminence, 135, 291, 449
mediobasal hypothalamus, 159
medulla, 231
medulla oblongata, 291
mesencephalon, 291
mesolimbic area, 355, 997
midbrain, 231, 1075
neostriatum, 1035
neural lobe, 135
neurohypophysis, 135
neurointermediate lobe, 69, 1035, 1045, 1093
nucleus accumbens, 49, 291, 371
nucleus of the diagonal band of Broca, 335
nucleus tractus solitarius, 327, 1173
occipital cortex, 947
olfactory bulb, 291
olfactory tubercles, 49
parabrachial nucleus, 327
parabrachial pontine complex, 267
paraventricular nucleus, 237, 327, 505
parietal cortex, 947
pars intermedia, 69
periaqueductal gray, 237, 327, 657, 701
piriform cortex, 355
pituitary, 45, 69, 135, 231, 523
pons, 231
pons medulla, 657
posterior hypophysis, 461
posterior hypothalamus, 237
prefrontal cortex, 49, 355
preoptic area, 291, 335
reticular formation, 237
rostral amygdala, 327
rostral hypothalamus, 159
rostral pars distalis, 135
rostral preoptic area, 721
septum, 237, 385
solitary tract nucleus, 677
striatum, 49, 231, 319, 355, 487, 657, 997
subicular system, 911
substantia nigra, 39, 49
substantia pars reticulata, 837
supraoptic region, 335
thalamus, 327, 355
tuberculum olfactorium, 371
vagus nerve, 677
ventral basal thalamus, 1015
ventral tegmental area, 49
ventral tegmentum, 237
ventromedial hypothalamus, 237
zona externa of the infundibulum, 335
zona incerta, 327
Brain, bovine, 657
A-18-F-NH_2
opioid antagonist characterization
opioid antagonist distribution
radioimmunoassay
Brain, cat, 569
avidin-biotin-peroxidase complex
hypothalamus
immunoreactivity
localization
neuropeptide Y
Brain, human, 77
co-localization
Met-enkephalin-Arg^6-Gly^7-Leu^8
neuropeptide Y
peptide immunoreactivity
pheochromocytomas
somatostatin
Brain, Met-enkephalin content, 355
analgesia
stress
Brain membranes, rat, 645
opiate receptors
opioid peptides
radioimmunoassay
Brain, monkey, 159
amygdala
hypothalamus
immunoreactive levels
neuropeptide Y
Brain, ostrich, 185
extrahypothalamic brain
gonadotropin-releasing hormone molecular forms
hypothalamus
Brain, primate, 335
GnRH-associated peptide
gonadotropin releasing prohormone
immunocytochemistry
immunostaining
peptide antisera
Brain, rabbit, 385
arginine vasopressin
body temperature
fever
septum
vasopressin antiserum
Brain, toad, 69
background adaptation
melanophore stimulating hormone
melanophore stimulating hormone release
pars intermedia
thyrotropin releasing hormone
Brainstem, 1173
cardiovascular control
opioid antagonist-like effects
α-MSH
Brainstem binding sites, 677
angiotensin receptors
nodose ganglionectomy
γ-Butyrolactone-γ-carbonyl-histidyl-prolinamide, 49
dopaminergic neurons
mesocortical system
mesolimbic system
nigrostriatal system
tyrosine hydroxylase

Calcitonin, 977
in vitro
pulmonary endocrine cells
Calcitonin gene-related peptide
capsaicin, 399
immunoreactivity, 399
rats, conscious, 747
renal blood flow
sensory neurons, 399
substance P, 399
vasodilation, 747
Calcium, 955
pigment dispersion
melanophore response
Capsaicin, 399
calcitonin gene-related peptide
immunoreactivity
sensory neurons
substance P
Capsacin-sensitive neurons, 1079
cardiovascular effects
guinea pigs
neurotensin
Carbamylcholine, 893
cholinergic receptors
thyroid cultures, human
vasoactive intestinal peptide
Cardiac output, 285
angina pectoris
atrial natriuretic factor
atrial natriuretic polypeptide
hemodynamic variables
human studies
pulmonary arterial pressure
Cardiac sarcolemma, 709
ATPase activity inhibition
drug interactions
morphine
opioid peptides
Cardiovascular control, 1173
brainstem
opioid antagonist-like effects
α-MSH
Cardiovascular effects
capsaicin-sensitive neurons, 1079
dynorphin A(1–13), 1089

guinea pigs, 1079
morphine bradycardia modulation, 1089
neurotensin, 1079
Cardiovascular responses, 1135
activity
alcohol
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Catalytic activity, 773
aminoterminal CNBr fragments
lactate dehydrogenase isoenzymes
reactivation agonists
reversed-phase HPLC
quaternary structure
Cats
acetorphan, 89
avidin-biotin peroxidase complex modification, 327
central nervous system, 327
coexistence, 103
enkephalins, 89
gastric releasing peptide, 423
gastric secretion, 89, 423
immunoreactivity, 327
α-melanocyte stimulating hormone, 327
motility, 423
neuropeptides, 103
peptide comparisons, 423
sympathetic preganglionic neurons, 103
CCK antagonist, 1061
dogs
L364718
Central control, 651
cholecystokinin octapeptide
dogs
food intake
water consumption
Central nervous system
avidin-biotin peroxidase complex modification, 327
blood-brain barrier, 261
cats, 327
cerebrospinal fluid, 261
cysteamine, 371
desglycinamide-arginine-vasopressin, 261
human studies, 261
immunohistochemistry, 371
immunoreactivity, 327
α-melanocyte stimulating hormone, 327
peptide antisera, 371
somatostatin-like immunoreactivity, 371
Cerebral ischemia, 769
cholecystokinin
gerbils
proglumide
stroke index score
Cerebrospinal fluid
Alzheimer's disease, 593
angiotensin I, 939
angiotensin II, 939
blood-brain barrier, 261
central nervous system, 261
desglycinamide-arginine-vasopressin, 261
dogs, 939
high performance liquid chromatography, 939
human plasma, 593
human studies, 261
pituitary protein, 593
plasma, 939
Ceruletide, 455
body weight
double-blind study
food intake
human studies, obese females
hunger
obesity
Chicks
avian feeding patterns, 585
eating, 823
intracerebroventricular injection, 823
narcolepsy, 585
neonatal exposure, 585
neuropeptide Y, 823
pancreatic polypeptides, 585
peptide YY, 823
tonic-clonic convulsions, 585
Chief cells, 391
autoradiography
binding sites
gastric mucosa
^{125}I-iodotyrosyl gastrin I, 391
parietal cells
Cholecystokinin
anorexia, tumor-induced, 223
behavioral tolerance, 223
cerebral ischemia, 769
circling behavior, 989
drinking, 763
drug interaction, 989
eating, 223, 763
flexion reflex, 153
gastrectomy, 801
gerbils, 769
high affinity binding sites, 109
human studies, 801
morphine, 153
naloxone, 763
nociception, 153
pancreatic secretion, 1023
peptide/pseudo-peptide analogs, 1023
proglumide, 769
region-specific antibodies, 801
small cell lung cancer cells, 109
spinal cord, 153
stroke index score, 769
substance P, 153
vasopressin deficiency, 763
Cholecystokinin octapeptide
central control, 651
contractile activity, 127
dogs, 651
food intake, 651, 845
footshock, 25
in vitro, 127
obesity, 845
passive avoidance, 25
pharmacological examination, 127
proglumide, 25
pylorus, 127
sex differences, 845
water intake, 651, 845
Cholecystokinin precursor, 95
immunohistochemistry studies
ProCCK flanking peptide
radioimmunoassay studies
rat gut
Cholinergic analgesia, 299
hypothermia
neuromodulatory effects
pain
swim analgesia
thyrotropin-releasing hormone
Cholinergic receptors, 893
carbamylcholine
thyroid cultures, human
vasoactive intestinal peptide
Circadian patterns, 347
DNA synthesis
epidermal growth factor
fasting
[^{3}H]-thymidine
Circling behavior, 989
cholecystokinin
drug interaction
CNS-mediated inhibition, 1029
[D-Ala^2,Met^5]-enkephalinamide
ion transport
prostaglandin-stimulated intestinal fluid
Cocaine, 819
adrenocorticotropic hormone
corticosterone
corticotropin releasing factor-like immunoreactivity
β-endorphin
hypothalamus
Coexistence, 103
cats
neuropeptides
sympathetic preganglionic neurons
Co-localization, 77
brain, human
Met-enkephalin-Arg^6-Gly^7-Leu^8
neuropeptide Y
peptide immunoreactivity
pheochromocytomas
somatostatin
Conditioned avoidance, 39
cyclo (Leu-Gly)
dopamine receptors
haloperidol
lesions, 6-hydroxydopamine
stereotypy, drug induced
Contractile action, 251
dilatory action
human mesenteric blood vessels
neuropeptides
Contractile activity, 127
cholecystokinin-octapeptide
in vitro
pharmacological examination
pylorus
Coronary artery, 477

arteries, rat/bovine comparisons
mesenteric artery
radioligand binding study
vasoactive intestinal receptors
Coronary pressure, 695
isolated rat hearts
morphine
naloxone
opioid peptides
Corticosterone, 819
adrenocorticotropic hormone
cocaine
corticotropin releasing factor-like immunoreactivity
β-endorphin
hypothalamus
Corticosterone secretion, 113
ACTH secretion
CRF release
(D-Ala^2,Met^5)-enkephalinamide
Corticotropin-releasing factor
adrenal medulla, 437
adrenocotricotropic factor, 841
aggression, 935
cyclic AMP, 927
dogs, 1011
dopamine beta-hydroxylase, 437
gastric emptying, 1011
grooming, 841
isolation, 935
pancreatic secretion, 1011
phenethanol N-methyltransferase, 437
plasma corticosterone, 437
POMC gene expression, 927
rat/mice comparisons, 841
route of administration, 437
sauvagine, 935
social behavior, 935
tumor cells, 927
Corticotropin releasing factor-like immunoreactivity, 819
adrenocorticotropic hormone
cocaine
corticosterone
β-endorphin
hypothalamus
CRF release, 113
ACTH secretion
corticosterone secretion
(D-Ala^2,Met^5)-enkephalinamide
C-terminal glucopeptide, 757
hypothalamus-neurohypophyseal system
in-vivo biosynthesis
C-terminals, 961
neurotensin metabolism
N-terminals
renal functions
Cumulus-oocyte complexes, 29
granulose cells
plasminogen activator activity, tissue type
plasminogen activator activity, urinary type
vasoactive intestinal peptide
Cycle (Leu-Gly), 39
conditioned avoidance
dopamine receptors
haloperidol
lesions, 6-hydroxydopamine
stereotypy drug induced
Cyclic AMP
anterior pituitary, 199
corticotropin releasing factor, 927
desensitization, 199
growth hormone, 199
growth hormone-releasing factor, 199
guinea pig pancreatic acini, 633
POMC gene expression, 927
secretin receptors, 633
somatostatin, 199
tumor cells, 927
vasoactive intestinal peptide receptors, 633
Cysteamine, 371
central nervous system
immunohistochemistry
peptide antisera
somatostatin-like immunoreactivity

Degradation, 599
aggregation
delta sleep-inducing peptide
delta sleep-inducing peptide analogues
plasma, human
plasma, rat
Delta sleep-inducing peptide
aggregation, 599
degradation, 599
delta sleep-inducing peptide analogues, 599
growth hormone release, 45
hypothalamus, 45
ovariectomy, 45
pituitary, 45
plasma, human, 599
plasma, rat, 599
Delta sleep-inducing peptide analogues, 599
aggregation
degradation
delta sleep-inducing peptide
plasma, human
plasma, rat
Density gradient, 829
bag cell neurons
neuropeptides
neurosecretory granules
Dependence, 1135
activity
alcohol
cardiovascular responses
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Desensitization, 199
anterior pituitary
cyclic AMP
growth hormone
growth hormone-releasing factor
somatostatin
Desglycinamide-arginine-vasopressin, 261
blood-brain barrier
central nervous system
cerebrospinal fluid
human studies
Desglycinamide vasopressin, 785
arginine vasopressin
exploratory activity
novel environment
Dihydrosomatostatin, 849
guinea pig brains
somatostatin-like immunoreactivity
Dilatory action, 251
contractile action
human mesenteric blood vessels
neuropeptides
Distribution, 779
neuromedin U
Diuresis, 811
analgesia
dynorphin analog
receptor selectivity
DNA synthesis, 347
circadian patterns
epidermal growth factor
fasting
[^{3}H]-thymidine
Dogs
angiotensin I, 939
angiotensin II, 939
bombesin, 973
CCK antagonist, 1061
central control, 651
cerebrospinal fluid, 939
cholecystokinin octapeptide, 651
corticotropin-releasing factor, 1011
electrolytes, 619
food intake, 651
gastric emptying, 1011
high performance liquid chromatography, 939
intestinal absorption, 619
L364718, 1061
lactation, 411
osmoregulation, 1003
oxytocin levels, 411
pancreatic exocrine secretion, 973
pancreatic polypeptide-antiserum, 973
pancreatic secretion, 1011
plasma, 939
somatostatin, 619
suckling, 411
thirst impairment, 1003
vasoactive intestinal peptide levels, 411
vasopressin antagonists, 1003
water consumption, 651
Dopamine beta-hydroxylase, 437
adrenal medulla
corticotropin-releasing factor
phenethanol N-methyltransferase
plasma corticosterone
route of administration
Dopamine neurotransmission, 487
Met-enkephalin
reciprocal response
striatum
Dopamine receptors
[^{3}H]apomorphine binding, 319
conditioned avoidance, 39
cyclo (Leu-Gly), 39

estrogen levels, 997
haloperidol, 39
in vitro, 319
lesions, 6-hydroxydopamine, 39
MIF-1 antagonism, 997
receptor modulation, 319
receptor-receptor interaction, 319
[^{3}H]spiperone binding, 319
stereotypy, drug induced, 39
thyrotropin-releasing hormone, 319
Dopaminergic neurons, 49
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide
mesocortical system
mesolimbic system
nigrostriatal system
tyrosine hydroxylase
Dorsal root ganglia, 565
Met-enkephalin
post-synaptic potentials
spinal cord cultures
Dose-dependent effects, 863
bradykinin
epicardial application
guinea pigs
pressor effects
tachycardia
Double-blind study, 455
body weight
ceruletide
food intake
human studies, obese females
hunger
obesity
Down regulation, 855
haloperidol
PLG analogs
striatal dopamine receptor
supersensitivity
Drinking
activity, 1135
alcohol, 1135
cardiovascular responses, 1135
cholecystokinin, 763
dependence, 1135
eating, 1135
endogenous opiates, review, 1135
epilepsy, 1135
immune system, 1135
learning, 1135
memory, 1135
mental illness, 1135
naloxone, 763
respiration, 1135
schizophrenia, 1135
sex, 1135
social behavior, 1135
stress, 1135
stroke, 1135
temperature, 1135
tolerance, 1135
vasopressin, deficiency, 763
Drug
acetorphan, 89
aluminum, 899
4-aminopyridine, 127
apomorphine, 39, 127, 319
atropine, 13, 443, 863
atropine sulfate, 127
bactopeptone, 89
bromopheniramine, 127
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide, 49
capsaicin, 863
carbachol, 55
carbamylcholine, 893
chlorpheniramine, 127
cholecystokinin, 989
cimetidine, 127, 863
cocaine, 819
cyproheptadine, 127
cysteamine, 371
2-deoxy-D-glucose, 89
diisopropylfluorophosphate, 21
diketopiperazine, 299
dopamine, 127, 319, 989
ethanol, 467
ethylene glycol bis(2-aminoethyl-ether)-tetraacetic acid, 21
ethylenediaminetetraacetic acid, 21
forskolin, 35
haloperidol, 39, 127, 855
hexamethonium, 13
histamine, 89, 127, 473
6-hydroxydopamine, 145
indomethacin, 863
insulin, 651
(+) isoproterenol, 127
(−) isoproterenol, 127
ketanserin, 127
L364718, 1061
lidocaine, 863
mefenamic acid, 443
mepyramine, 863
metapyrilene, 127
methylatropine, 55
morphine, 153, 695, 709, 869, 905, 1089, 1165
muscimol, 905
naloxone, 1, 89, 153, 309, 355, 431, 585, 609, 613, 651, 695, 709, 811, 837, 863, 905, 1029, 1165
naltrexone, 811
nicotin, 1035
nipecotic, 905
norepinephrine, 585
ORG.2766, 415, 1057
pertussin toxin, 199
o-phenanthroline, 21
phentolamine, 863, 905
phenyl methane sulfonyl fluoride, 21
pilocarpine, 299
pimozide, 45
prazosin, 127
proglumide, 25, 989
propranolol, 863, 1011
L-propranolol, 55
quipazine, 127
reserpine, 905
RX77368, 299
serotonin, 127
spantide, 127
sulpiride, 127
(−)-sulpiride, 319
tetragastrin, 127
tetrodotoxin, 127
timolol, 127
[^{3}H]-thymidine, 347
tosyl lysylchloromethyl ketone, 21
(Tyr-D-Ala-Gly-Phe-NH)$_2$, 431
Tyr-D-Ala-Gly-Phe-NH-(CH$_2$)$_7$-HN-Phe-Gly-D-Ala-Tyr, 431
WIN 44, 441-3, 837
yohimbine, 127
zinterol, 127
Drug interaction
ATPase activity inhibition, 709
cardiac sarcolemma, 709
cholecystokinin, 989
circling behavior, 989
morphine, 709
opioid peptides, 709
Dynorphin, 191
analgesia
human studies, cancer patients
intrathecal administration
pain
Dynorphin-A
anterior pituitary, 367
anterior pituitary, bovine, 361
17β-estradiol, 367
immunoreactivity, 361, 367
in vitro, 361, 367
in vivo, 367
molecular weight, 361, 367
peptide release, 361, 367
sheep, 367
Dynorphin A (1–13), 1089
cardiovascular effects
morphine bradycardia modulation
Dynorphin A degradation, 701
in vitro
in vivo
opioid binding
Dynorphin A(1–8) levels, 1075
food deprivation
high fat diet
Dynorphin analog, 811
analgesia
diuresis
receptor selectivity
Dynorphin-induced circling, 837
in vivo
motor control
structure-activity relationship
substantia pars reticulata

Eating
activity, 1135
alcohol, 1135
anorexia, tumor-induced, 223
behavioral tolerance, 223
cardiovascular responses, 1135
chicks, 823
cholecystokinin, 223, 763
dependence, 1135
drinking, 1135
endogenous opiates, review, 1135
epilepsy, 1135
glucagon-(1–21), 943
immune system, 1135
intracerebroventricular injection, 823
learning, 1135
memory, 1135
mental illness, 1135
naloxone, 763
neuropeptide Y, 823
peptide YY, 823
respiration, 1135
satiety, 943
schizophrenia, 1135
sex, 1135
social behavior, 1135
spasmolysis, 943
stress, 1135

stroke, 1135
temperature, 1135
tolerance, 1135
vasopressin deficiency, 763
Electroconvulsive shock, 605
amnesia
β-endorphin
memory disruption
Electrolytes, 619
dogs
intestinal absorption
somatostatin
Electrophysiology, 415
melanocortins
ORG.2766
sciatic nerve regeneration
Endogenous antipyretic response, 501
febrile response
α-melanocyte stimulating hormone
rabbits
Endogenous opiates, review, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
β-Endorphin
adrenocorticotropic hormone, 819
amnesia, 605
cocaine, 819
corticosterone, 819
corticotropin releasing factor-like immunoreactivity, 819
electroconvulsive shock, 605
beta-endorphin-(1–27), 123
Met-enkephalin, 1119
hypothalamus, 819
hypothermia, 123
memory disruption, 605
posterior pituitary, amphibian, 1119
radioimmunoassay, 1119
beta-Endorphin-(1–27), 123
beta-endorphin
hypothermia
b-Endorphin metabolism, 467
ethanol
purified synaptosomal plasma membranes
Energy deficiency, 175
exercise
human study
sleep deprivation
VIP plasma levels
Enkephalin bioactivity, 1035
enzymic hydrolysis
native/cryptic enkephalin concentrations
nicotine-induced alterations
Enkephalin dimers, 431
body temperature
hypothermia
Enkephalin metabolism, 523
aminopeptidase M
blood vessels
immunohistochemistry
localization, enzyme
localization, peptide
pituitary
Met-Enkephalin
blood brain barrier, 899
dopamine neurotransmission, 487
dorsal root ganglia, 565
β-endorphin, 1119
hemodynamic responses, 609
human studies, 609
opiate receptors, 609
post-synaptic potentials, 565
posterior pituitary, amphibian, 1119
radioimmunoassay, 1119
reciprocal response, 487
spinal cord cultures, 565
striatum, 487
transport system, 899
TYR-MIF-1, 899
Met-Enkephalin-Arg^6-Gly^7-Leu^8, 77
brain, human
co-localization
neuropeptide Y
peptide immunoreactivity
pheochromocytomas
somatostatin
(D-Ala^2,Met^5)Enkephalinamide, 113
ACTH secretion
corticosterone secretion
CRF release
Enkephalins, 89
acetorphan
cats
gastric secretion
Enzymatic radioiodination, 663
peptide chemical characterization
peptide purification
Enzymic hydrolysis, 1035
enkephalin bioactivity
native/cryptic enkephalin concentrations
nicotine-induced alterations
Epicardial application, 863
bradykinin
dose-dependent effects
guinea pigs
pressor effects
tachycardia
Epidermal growth factor
biological potency, 877
circadian patterns, 347
DNA synthesis, 347
fasting, 347
mitogenesis, 877
N-terminal heterogenecity, 877
receptor binding, 877
[^{3}H]-thymidine, 347
thyroid hormone secretion, 743
Epilepsy, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
17β-Estradiol, 367
anterior pituitary
dynorphin-A
immunoreactivity
in vitro
in vivo
molecular weight
peptide release
sheep
Estrogen levels, 997
dopamine receptors
MIF-1 antagonism
Ethanol, 467
β-endorphin metabolism
purified synaptosomal plasma membranes
Exercise, 175
energy deficiency
human study
sleep deprivation
VIP plasma levels
Exocrine pancreatic secretion, 967
glucagon
oxyntomodulin
Exploratory activity, 785
arginine vasopressin
desglycinamide vasopressin
novel environment
Extrahypothalamic brain, 185
brain, ostrich
gonadotropin-releasing hormone molecular forms
hypothalamus

F-8-F-NH_2, 657
A-18-F-NH_2
brain, bovine
opioid antagonist characterization
opioid antagonist distribution
radioimmunossay
Fasting, 347
circadian patterns
DNA synthesis
epidermal growth factor
[^{3}H]-thymidine
Febrile response, 501
endogenous antipyretic response
α-melanocyte stimulating hormone
rabbits
Feeding behavior, 237
anorexia
bombesin
hypothalamus
Fever, 385
arginine vasopressin
body temperature
brain, rabbit
septum
vasopressin antiserum

Fishes, bony, 135
antiserum specificity
hypothalamus
immunoreactivity
neurotensin
pituitary
[^{125}I]FK33824, 1015
autoradiography
mu opioid binding sites
Flexion reflex, 153
cholecystokinin
morphine
nociception
spinal cord
substance P
FMRFamide
FMRFamide-like peptides, 515
FMRF-related peptide, 533
snails, 515, 533
FMRFamide-like peptides, 515
FMRFamide
snails
FMRFamide receptors, 1065
Helix neurons
radioreceptor assay
FMRF-related peptide, 533
FMRFamide
snails
Food deprivation, 1075
dynorphin A(1–8) levels
high fat diet
Food intake
body weight, 455
central control, 651
ceruletide, 455
cholecystokinin octapeptide, 651, 845
dogs, 651
double-blind study, 455
human studies, obese females, 455
hunger, 455
obesity, 455, 845
sex differences, 845
water consumption, 651, 845
Footshock
cholecystokinin octapeptide, 25
oxytocin, 243
passive avoidance, 25
plasma levels, 243
proglumide, 25
spinal cord, 243
vasopressin, 243
Fundus plasma membranes, 195
neurotensin receptors
synaptosomal membranes brain
target size analysis

GABA release, 905
analgesia, non-opioid
neo-kyotorphin
Gastrectomy, 801
cholecystokinin
human studies
region-specific antibodies
Gastric acid secretion, 575
human corticotropin-releasing factor
in vitro
in vivo
pancreatic secretion
Gastric emptying, 1011
corticotropin-releasing factor
dogs
pancreatic secretion
Gastric motility
arterial pressure, 887
bombesin, 887
hypothalamus, 505
nucleus tractus solitarius, 887
oxytocin, 505
paraventricular nucleus, 505
stimulatory effects, 505
thyrotropin releasing hormone, 505
Gastric mucosa, 391
autoradiography
binding sites
chief cells
^{125}I-iodotyrosyl gastrin I
parietal cells
Gastric secretion
acetorphan, 89
cats, 39, 423
enkephalins, 89
gastric releasing peptide, 423
motility, 423
peptide comparisons, 423
Gastrin releasing peptide
cats, 423
gastric secretion, 423
glucagon secretion, basal, 55
glucagon secretion, stimulated, 55
insulin secretion, basal, 55
insulin secretion, stimulated, 55
motility, 423
peptide comparisons, 423
Gastrointestinal tract, 145
adrenergic neurons
immunoreactivity
neuropeptide Y
Gerbils, 769
cerebral ischemia
cholecystokinin
proglumide
stroke index score
Glucagon, 967
exocrine pancreatic secretion
oxyntomodulin
Glucagon-(1–21), 943
satiety
spasmolysis
Glucagon secretion, basal, 55
gastrin releasing peptide
glucagon secretion, stimulated
insulin secretion, basal
insulin secretion, stimulated
Glucagon secretion, stimulated, 55
gastrin releasing peptide
glucagon secretion, stimulated
insulin secretion, basal
insulin secretion, stimulated
GnRH-associated peptide, 335
brain, primate
gonadotropin releasing prohormone
immunocytochemistry
immunostaining
peptide antisera
Goats, 807
luteal regression
neurophysin secretion
oxytocin release
Gonadectomy, 721
LHRH-immunopositive neurons
plasma LH levels
Gonadotropin releasing hormone
anterior pituitary, 543
gonadotropin releasing hormone
associated peptide, 21
immunoreactivity, 543
long-term primary cultures, 543
peptide distribution, 543
processing enzymes, 21
substrate specificity, 21
thyrotropin releasing hormone, 543
Gonadotropin releasing hormone
associated peptide, 21
gonadotropin releasing hormone
processing enzymes
substrate specificity
Gonadotropin-releasing hormone
molecular forms, 185
brain, ostrich
extrahypothalamic brain
hypothalamus
Gonadotropin releasing prohormone, 335
brain, primate
GnRH-associated peptide
immunocytochemistry
immunostaining
peptide antisera
Gonadotropin secretion, 539
anterior pituitary gland
neuropeptide Y
pancreatic polypeptide
rats, males
Granulose cells, 29
cumulus-oocyte complexes
plasminogen activator activity, tissue type
plasminogen activator activity, urinary type
vasoactive intestinal peptide
Grooming, 841
adrenocorticotropic hormone
corticotropin-releasing factor
rat/mice comparisons
Growth hormone
anterior pituitary, 199
cyclic AMP, 199
desensitization, 199
growth hormone-releasing factor, 199
immunocytochemistry, 1127
somatostatin, 199, 1127
strain differences, 1127
Growth hormone release, 45
delta sleep-inducing peptide
hypothalamus
ovariectomy
pituitary
Growth hormone-releasing factor, 199
anterior pituitary
cyclic AMP
desensitization
growth hormone
somatostatin
Growth hormone secretion, 35
in vitro
in vivo
lesions, mediobasal hypothalamus
vasoactive intestinal peptide
Guinea pig brains, 849
dihydrosomatostatin
somatostatin-like-immunoreactivity
Guinea pig ileum, 169
neurokinins
peptide comparisons
rat duodenum
smooth muscle contraction
structure-activity relationship

substance P
tackykinins
Guinea pig pancreatic acini, 633
cyclic AMP
secretin receptors
vasoactive intestinal peptide receptors
Guinea pig pancreatic polypeptide, 165
pancreatic polypeptide content
pancreatic polypeptide structure
Guinea pigs
bradykinin, 863
capsaicin-sensitive neurons, 1079
cardiovascular effects, 1079
dose-dependent effects, 863
epicardial application, 863
neurotensin, 1079
pressor effects, 863
tachycardia, 863

Haloperidol
conditioned avoidance, 39
cyclo (Leu-Gly), 39
dopamine receptors, 39
down regulation, 855
lesions, 6-hydroxydopamine, 39
PLG analogs, 855
stereotypy, drug induced, 39
striatal dopamine receptor, 855
supersensitivity, 855
Heat acclimation, 715
human studies
plasma cortisol levels
plasma peptide responses
Helix neurons, 1065
FMRFamide receptors
radioreceptor assay
Hemodynamic responses, 609
human studies
methionine-enkephalin
opiate receptors
Hemodynamic variables, 285
angina pectoris
atrial natriuretic factor
atrial natriuretic polypeptide
cardiac output
human studies
pulmonary arterial pressure
High affinity binding
lung cancer cells, 1101
[^{3}H]neurotensin, 1169
uterus, 1169
vasoactive intestinal peptide receptors, 1101
High affinity binding sites, 109
cholecystokinin
small cell lung cancer cells
High fat diet, 1075
dynorphin A(1–8) levels
food deprivation
High performance liquid chromatography, 939
angiotensin I
angiotensin II
cerebrospinal fluid
dogs
plasma
Hippocampus, human, 911
immunocytochemistry
immunoreactive CCK distribution
Histamine, 473
in vitro
radioimmunoassay
stomach, rat
thyrotropin-releasing hormone release
Hormone
17β-estradiol, 361, 367
estradiol benzoate, 921
estrogen, 309
growth hormone, 35, 45, 199
insulin, 55
norepinephrine, 127
progesterone, 309, 361, 367, 807, 921
prostaglandin, 1029
testosterone, 159
Human corticotropin-releasing factor, 575
gastric acid secretion
in vitro
in vivo
pancreatic secretion
Human fetus, 947
binding sites
substance P
Human lymphocytes, 1165
morphine
naloxone
Tyr-MIF-1
Human medullary thyroid carcinoma cell line, 207
somatostatin 28(1–12)
Human mesenteric blood vessels, 251
contractile action
dilatory action
neuropeptides
Human plasma, 593
Alzheimer's disease
cerebrospinal fluid
pituitary protein
Human studies
angina pectoris, 285
atrial natriuretic factor, 285
atrial natriuretic polypeptide, 285
blood-brain barrier, 261
cardiac output, 285
central nervous system, 261
cerebrospinal fluid, 261
cholecystokinin, 801
desglycinamide-arginine-vasopressin, 261
energy deficiency, 175
exercise, 175
gastrectomy, 801
heat acclimation, 715
hemodynamic responses, 609
hemodynamic variables, 285
immunomodulation, 951
leukocyte migration inhibiting factor, 951
methionine-enkephalin, 609
opiate receptors, 609
plasma cortisol levels, 715
plasma peptide responses, 715
pulmonary arterial pressure, 285
RC-102, 951
region-specific antibodies, 801
sleep deprivation, 175
somatostatin, 951
VIP plasma levels, 175
Human studies, cancer patients, 191
analgesia
dynorphin
intrathecal administration
pain
Human studies, obese females, 455
body weight
ceruletide
double-blind study
food intake
hunger
obesity
Human studies, women, 797
vaginal blood flow
vaginal lubrication
vasoactive intestinal polypeptide
Hunger, 455
body weight
ceruletide
double-blind study
food intake
human studies, obese females
obesity
Hypertension
age differences, 231
blood pressure, 227
body temperature, 227
hyperthermia, 227
rats, spontaneously hypertensive, 227
receptor distribution, 231
strain differences, 231
supersensitivity, 227
thyrotropin releasing hormone, 227
Hypothalamic action, 449
atrial natriuretic factor
vasopressin secretion
Hypothalamus
adrenocorticotropic hormone, 819
amygdala, 159
anorexia, 237
antiserum specificity, 135
avidin-biotin-peroxidase complex, 569
bombesin, 237
brain, cats, 569
brain, monkey, 159
brain, ostrich, 185
cocaine, 819
corticosterone, 819
corticotropin releasing factor-like immunoreactivity, 819
delta sleep-inducing peptide, 45
extrahypothalamic brain, 185
β-endorphin, 819
feeding behavior, 237
fishes, bony, 135
gastric motility, 505
gonadotropin-releasing hormone molecular forms, 185
growth hormone release, 45
immunoreactive levels, 159
immunoreactivity, 135, 569
localization, 569
neuropeptide Y, 159, 569
neurotensin, 135
ovariectomy, 45
oxytocin, 505
paraventricular nucleus, 505
pituitary, 45, 135
stimulatory effects, 505
thyrotropin releasing hormone, 505
Hypothalamus-neurohypophyseal system, 757
C-terminal glucopeptide
in vivo biosynthesis
Hyperthermia, 227
blood pressure
body temperature
hypertension

rats, spontaneously hypertensive
supersensitivity
thyrotropin releasing hormone
Hypothermia
body temperature, 431
cholinergic analgesia, 299
beta-endorphin, 123
beta-endorphin-(1–27), 123
enkephalin dimers, 431
neuromodulatory effects, 299
pain, 299
swim analgesia, 299
thyrotropin-releasing hormone, 299

Immune system, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Immunocytochemistry
brain, primate, 335
GnRH-associated peptide, 335
gonadotropin releasing prohormone, 335
growth hormone, 1127
immunostaining, 335
neuropeptide Y immunoreactivity, 1107
peptide antisera, 335
somatostatin, 1127
strain differences, 1127
underlying white matter, 1107
visual cortex, human, 1107
Immunohistochemistry
aminopeptidase M, 523
blood vessels, 523
central nervous system, 371
cholecystokinin precursor, 95
cysteamine, 371
enkephalin metabolism, 523
hippocampus, human, 911
immunoreactive CCK distribution, 911
localization, enzyme, 523
localization, peptide, 523
peptide antisera, 371
pituitary, 523
proCCK flanking peptide, 95
radioimmunoassay studies, 95
rat gut, 95
somatostatin-like immunoreactivity, 371
Immunomodulation, 951
human studies
leukocyte migration inhibiting factor
RC-102
somatostatin
Immunoreactive CCK distribution, 911
hippocampus
immunocytochemistry
Immunoreactive levels, 159
amygdala
brain, monkey
hypothalamus
neuropeptide Y
Immunoreactivity
adrenergic neurons, 145
anterior pituitary, 367, 543
anterior pituitary, bovine, 361
antiserum specificity, 135
atrial natriuretic factor, 461
avidin-biotin peroixdase complex, 569
avidin-biotin peroxidase complex modification, 327
biological activity, 461
brain, cats, 569
calcitonin gene-related peptide, 399
capsaicin, 399
cats, 327
central nervous system, 327
dynorphin-A, 361, 367
17β-estradiol, 367
fishes, bony, 135
gastrointestinal tract, 145
gonadotropin releasing hormone, 543
hypothalamus, 135, 569
in vitro, 361, 367
in vivo, 367
localization, 569
long-term primary cultures, 543
α-melanocyte stimulating hormone, 327
molecular weight, 361, 367
neuropeptide Y, 145, 569
neurotensin, 135
peptide distribution, 543
peptide release, 361, 367
pituitary, 135
posterior hypophysis, 461
sheep, 367
sensory neurons, 399
substance P, 399
thyrotropin releasing hormone, 543
Immunostaining, 335
brain, primate
GnRH-associated peptide
gonadotropin releasing prohormone
immunocytochemistry
peptide antisera
In situ retrograde perfused heart, 257
atrial natriuretic peptide
right atrial pressure
vagotomy, bilateral
volume expansion
Insulin secretion, basal, 55
gastrin releasing peptide
glucagon secretion, basal
glucagon secretion, stimulated
insulin secretion, stimulated
Insulin secretion, stimulated, 55
gastrin releasing peptide
glucagon secretion, basal
glucagon secretion, stimulated
insulin secretion, basal
Intestinal absorption, 619
dogs
electrolytes
somatostatin
Intestinal transit, 613
analgesia
kintsin
opioid receptors
Intracerebroventricular injection, 823
chicks
eating
neuropeptide Y
peptide YY
Intrathecal administration
analgesia, 191
dynorphin, 191
human studies, cancer patients, 191
label distribution, 213
pain, 191
spinal cord, 213
^{125}I-substance P, 213
In vitro
anterior pituitary, 367
anterior pituitary, bovine, 361
[^{3}H]apomorphine binding, 319
basal conditions, 291
calcitonin, 977
cholecystokinin-octapeptide, 127
contractile activity, 127
dopamine receptors, 319
dynorphin-A, 361, 367
17β-estradiol, 367
gastric acid secretion, 575
growth hormone secretion, 35
histamine, 473
human corticotropin-releasing factor, 575
immunoreactivity, 361, 367
in vivo, 35, 367, 575
lesions, mediobasal hypothalamus, 35
molecular weight, 361, 367
MSH release regulation, 1093
neurointermediate lobe, 1093
pancreatic secretion, 575
peptide release, 361, 367
pharmacological examination, 127
pulmonary endocrine cells, 977
pylorus, 127
radioimmunoassay, 473
receptor modulation, 319
receptor-receptor interaction, 319
regional distribution, 291
sheep, 367
[^{3}H]spiperone binding, 319
stimulated conditions, 291
stomach, rat, 473
thyrotropin-releasing hormone, 291, 319
thyrotropin-releasing hormone release 473
vasoactive intestinal peptide, 35
Xenopus laevis, 1093
In vivo
anterior pituitary, 367
arteriolar dilation, 443
dynorphin-A, 367, 701
dynorphin-induced circling, 837
17β-estradiol, 367
gastric acid secretion, 575
growth hormone secretion, 35
human corticotropin-releasing factor, 575
immunoreactivity, 367
in vitro, 35, 367, 575, 701
lesions, mediobasal hypothalamus, 35
MIF-1, 1051
molecular weight, 367

motor control, 837
muscarinic receptor stimulation, 443
opioid binding, 701
opioid bladder effects, 625
pancreatic secretion, 575
parathyroid hormone fragments, 443
peptide release, 367
Pro-Leu-Gly, 1051
sheep, 367
somatostatin analog, 625
striatal dopamine receptor binding, 1051
structure-activity relationship, 837
substantia pars reticulata, 837
tolerance, 1051
Tyr-Pro-Leu-Gly, 1051
vasoactive intestinal peptide, 35
In vivo biosynthesis, 757
C-terminal glucopeptide
hypothalamus-neurohypophyseal system
^{125}I-Iodotyrosyl gastrin I, 391
autoradiography
binding sites
chief cells
gastric mucosa
parietal cells
Ion transport, 1029
CNS-mediated inhibition
[D-Ala^3,Met^5]-enkephalinamide
prostaglandin-stimulated intestinal fluid
Isolated rat hearts, 695
coronary pressure
morphine
naloxone
opioid peptides
Isolation, 935
aggression
corticotropin releasing factor
sauvagine
social behavior

Kentsin, 613
analgesia
intestinal transit
opioid receptors

L364718, 1061
CCK antagonist
dogs
Label distribution, 213
intrathecal administration
spinal cord
^{125}I-substance P
Lactate dehydrogenase isoenzymes, 773
aminoterminal CNBr fragments
catalytic activity
reactivation agonists
reversed phase HPLC
quaternary structure
Lactation, 411
dogs
oxytocin levels
suckling
vasoactive intestinal peptide levels
Learning, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Lesions, 6-hydroxydopamine, 39
conditioned avoidance
cyclo (Leu-Gly)
dopamine
haloperidol
stereotypy, drug induced
Lesions, mediobasal hypothalamus, 35
growth hormone secretion
in vitro
in vivo
vasoactive intestinal peptide
Leukocyte migration inhibiting factor, 951
human studies
immunomodulation
RC-102
somatostatin
LHRH-immunopositive neurons, 721
gonadectomy
plasma LH levels
Localization, 569
avidin-biotin-peroxidase complex
brain, cats
hypothalamus
immunoreactivity
neuropeptide Y
Localization, enzyme, 523
aminopeptidase M
blood vessels
enkephalin metabolism
immunohistochemistry
localization, peptide
pituitary
Localization, peptide, 523
aminopeptidase M
blood vessels
enkephalin metabolism
immunohistochemistry
localization, enzyme
pituitary
Long-term primary cultures, 543
anterior pituitary
gonadotropin releasing hormone
immunoreactivity
peptide distribution
thyrotropin releasing hormone
Lordosis, 309
opioid receptors
ovariectomy
Lung cancer cells, 1101
high affinity binding
vasoactive intestinal peptide receptors
Luteal regression, 807
goats
neurophysin secretion
oxytocin release

Melanocortins
electrophysiology, 415
neurotropic effect, 581
nerve regeneration, 581
ORG.2766, 415
sciatic nerve regeneration, 415
Melanophore response, 955
calcium
pigment dispersion
α-Melanocyte stimulating hormone
avidin-biotin peroxidase complex modification, 327
brainstem, 1173
cardiovascular control, 1173
cats, 327
central nervous system, 327
endogenous antipyretic response, 501
febrile response, 501
immunoreactivity, 327
opioid antagonist-like effects, 1173
rabbits, 501
Melanophore stimulating hormone
amphibians, 61
background adaptation, 69
brain, toads, 69
melanophore stimulating hormone release, 69
neuropeptide Y, 61
pars intermedia, 69
secretion regulation, 61
thyrotropin releasing hormone, 69
Melanophore stimulating hormone release, 69
background adaptation
brain, toads
melanophore stimulating hormone
pars intermedia
thyrotropin releasing hormone
Memory, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Memory disruption, 605
amnesia
electroconvulsive stock
β-endorphin
Memory retrieval, 493
arginine vasopressin
prenatal administration
sexual dimorphism
Mental illness, 1135
activity
alcohol
cardiovascular responses
dependence
drinking

eating
endogenous opiates, review
epilepsy
immune system
learning
memory
respiration
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Mesenteric artery, 477
arteries, rat/bovine comparisons
coronary artery
radioligand binding study
vasoactive intestinal receptors
Mesocortical system, 49
γ-butyrolactone-γ-carboxyl-histidyl-prolinamide
dopaminergic neurons
mesolimbic system
nigrostriatal system
tyrosine hydroxylase
Mesolimbic system, 49
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide
dopaminergic neurons
mesocortical system
nigrostriatal system
tyrosine hydroxylase
Met-enkephalin
blood-brain barrier, 899
β-endorphin, 1119
posterior pituitary, amphibian, 1119
radioimmunoassay, 1119
transport system, 899
Tyr-MIF-1, 899
Method
autoradiography, 213, 391, 737, 1015
avidin-biotin peroxidase complex modification, 327
chromatography, 779, 801
computer-assisted image analysis, 371
electron microscopic immunohistochemistry, 77
electron microscopy, 135
fibrin overlay technique, 29
FMRFamide, 515
footshock, 25
gel chromatography, 533
gel filtration, 207, 599, 639
high performance liquid chromatography, 7, 185, 291, 399, 467, 515, 533, 663, 757, 849, 939
immunocytochemistry, 61, 135, 145, 327, 335, 543, 569, 687, 911, 1093, 1107, 1127
immunohistochemistry, 69, 95, 103, 371, 399, 461, 523
immunostaining, 335
ion exchange high performance liquid chromatography, 179
lactoperoxide-glucose oxidase, 663
light microscopic immunohistochemistry, 77
light microscopy, 543
luteinizing hormone-releasing activity assessment, 185
microfluorimetry, 371
peroxidase-antiperoxidase technique, 911
radioimmunoassay, 7, 61, 69, 95, 159, 207, 243, 291, 385, 399, 461, 473, 515, 533, 639, 645, 657, 779, 801, 819, 849, 983, 1035, 1119
radioimmunoassay with region specific antisera, 185
radioligand binding study, 477
reverse phase high performance liquid chromatography, 207, 461, 701, 877
reversed-phase HPLC, 773
sodium dodecyl sulfate polyacrylamide gel electrophoresis, 29
target size analysis by radiation inactivation, 195
television microscopy, 443
ultraviolet spectrometry, 791
MIF-1
γ-aminobutyric acid, 751
benzodiazepine receptor binding, 751
in vivo, 1051
Pro-Leu-Gly, 1051
striatal dopamine receptor binding, 1051
tolerance, 1051
Tyr-MIF-1, 751
Tyr-Pro-Leu-Gly, 1051
MIF-1 antagonism, 997
dopamine receptors
estrogen levels
Mitogenesis, 877
biological potency
epidermal growth factor
N-terminal heterogenecity
receptor binding
Molecular heterogeneity, 639
neurotensin-like immunoreactivity
porcine ileal mucosa
Molecular weight
anterior pituitary, 367
anterior pituitary, bovine, 361
dynorphin-A, 361, 367
17β-estradiol, 367
immunoreactivity, 361, 367
in vitro, 361, 367
in vivo, 361, 367
peptide release, 361, 367
sheep, 361, 367
Monoamine components, 267
neuropeptide components
parabrachial pontine complex
Morphine
ATPase activity inhibition, 709
cardiac sarcolemma, 709
cholecystokinin, 153
coronary pressure, 695
drug interactions, 709
flexion reflex, 153
human lymphocytes, 1165
isolated rat hearts, 695
naloxone, 695, 1165
nociception, 153
opioid peptides, 695, 709
spinal cord, 153
substance P, 153
Tyr-MIF-1, 1165
Morphine antagonism, 869
octapeptide analogs
opiate binding
somatostatin
Morphine bradycardia modulation, 1089
cardiovascular effects
dynorphin A (1–13)
Motility, 423
cats
gastric releasing peptide
gastric secretion
peptide comparisons
Motor control, 837
dynorphin-induced circling
in vivo
structure-activity relationship
substantia pars reticulata
Mouse cell cultures, 559
opiate receptors
spinal cord neurons
Muscarinic receptor stimulation, 443
arteriolar dilation
in vivo
parathyroid hormone fragments
MSH release regulation, 1093
in vitro
neurointermediate lobe
Xenopus laevis

Naloxone
cholecystokinin, 763
coronary pressure, 695
drinking, 763
eating, 763
human lymphocytes, 1165
isolated rat hearts, 695
morphine, 695, 1165
non-opioid analgesia, 1
opioid analgesia, 1
opioid peptides, 695
prolyl-leucyl-glycinamide, 1
snails, 1
stress-induced analgesia, 1
Tyr-MIF-1, 1165
tyrosine-prolyl-leucyl-glycinamide, 1
vasopressin deficiency, 763
Narcolepsy, 585
avian feeding patterns
chicks
neonatal exposure
pancreatic polypeptides
tonic-clonic convulsions
Native/cryptic enkephalin concentrations, 1035
enkephalin bioactivity
enzymic hydrolysis
nicotine-induced alterations
Neo-kyotorphin, 905
analgesia, non-opioid
GABA release
Neonatal exposure, 585
avian feeding patterns
chicks
narcolepsy
pancreatic polypeptides
tonic-clonic convulsions
Nerve regeneration, 1057
Org 2766
route of administration
sciatic nerve damage
Neurointermediate lobe
N-acetylated endorphins, 1045
anterior pituitary, 1045
in vitro, 1093
MSH release regulation, 1093
sheep pituitary, 1045

Xenopus laevis, 1093
Neurokinins, 169
guinea pig ileum
peptide comparisons
rat duodenum
smooth muscle contraction
structure-activity relationship
substance P
tachykinins
Neuromedin U, 779
distribution
Neuromodulatory effects, 299
cholinergic analgesia
hypothermia
pain
swim analgesia
thyrotropin-releasing hormone
Neuron development, 687
neuronal cell death
neuronal survival
structural specificity
Neuronal cell death, 687
neuron development
neuronal survival
structural specificity
Neuronal survival, 687
neuron development
neuronal cell death
structural specificity
Neuropeptides
bag cell neurons, 829
cats, 103
coexistence, 103
contractile action, 251
density gradient, 829
dilatory action, 251
human mesenteric blood vessels, 251
neurosecretory granules, 829
sympathetic preganglionic neurons, 103
Neuropeptide components, 267
monoamine components
parabrachial pontine complex
Neuropeptide effects, 921
ovariectomy
plasma LH levels
Neuropeptide Y
adrenergic neurons, 145
amphibians, 61
amygdala, 159
anterior pituitary gland, 539
avidin-biotin-peroxidase complex, 569
brain, cats, 569
brain, human, 77
brain, monkey, 159
chicks, 823
co-localization, 77
eating, 823
Met-enkephalin-Arg^6-Gly^7-Leu^8, 77
gastrointestinal tract, 145
gonadotropin secretion, 539
hypothalamus, 159, 569
immunoreactive levels, 159
immunoreactivity, 145, 569
intracerebroventricular injection, 823
localization, 569
melanophore-stimulating hormone, 61
neuropeptide Y, 823
pancreatic polypeptide, 539
peptide immunoreactivity, 77
peptide YY, 823
pheochromocytomas, 77
rats, males, 539
secretion regulation, 61
somatostatin, 77
Neuropeptide Y immunoreactivity, 1107
immunocytochemistry
underlying white matter
visual cortex, human
Neurophysin secretion, 807
goats
luteal regression
oxytocin release
Neurosecretory granules, 829
bag cell neurons
density gradient
neuropeptides
Neurotensin
antiserum specificity, 135
cardiovascular effects, 1079
capsaicin-sensitive neurons, 1079
fishes, bony, 135
guinea pigs, 1079
hypothalamus, 135
immunoreactivity, 135
pituitary, 135
[^{3}H]Neurotensin, 1169
high affinity binding
uterus
Neurotensin-like immunoreactivity, 639
molecular heterogeneity
porcine ileal mucosa
Neurotensin metabolism, 961
C-terminals
N-terminals
renal functions
Neurotensin receptors, 195
fundus plasma membranes
synaptosomal membranes, brain
target size analysis
Neurotropic effect, 581
melanocortins
nerve regeneration
Nerve regeneration, 581
melanocortins
neurotropic effect
Nicotine-induced alterations, 1035
enkephalin bioactivity
enzymic hydrolysis
native/cryptic enkephalin concentrations
Nigrostriatal system, 49
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide
dopaminergic neuron
mesocortical system
mesolimbic system
tyrosine hydroxylase
Nociception, 153
cholecystokinin
flexion reflex
morphine
spinal cord
substance P
Nodose ganglionectomy, 677
angiotensin receptors
brainstem binding sites
Non-opioid analgesia, 1
naloxone
opioid analgesia
prolyl-leucyl-glycinamide
snails
stress-induced analgesia
tyrosine-prolyl-leucyl-glycinamide
Novel environment, 785
arginine vasopressin
desglycinamide vasopressin
exploratory activity
N-terminal heterogenecity, 877
biological potency
epidermal growth factor
mitogenesis
receptor binding
N-terminals, 961
C-terminals
neurotensin metabolism
renal functions
Nucleus tractus solitarius, 887
arterial pressure
bombesin
gastric motility

Obesity
body weight, 455
ceruletide, 455
cholecystokinin octapeptide, 845
double-blind study, 455
food intake, 455, 845
human studies, obese females, 455
hunger, 455
sex differences, 845
water intake, 845
Octapeptide analogs, 869
morphine antagonism
opiate binding
somatostatin
Opiate binding, 869
morphine antagonism
octapeptide analogs
somatostatin
Opiate receptors
brain membranes, rat, 645
hemodynamic responses, 609
human studies, 609
methionic-enkephalin, 609
mouse cell cultures, 559
opioid peptides, 645
radioimmunoassay, 645
spinal cord neurons, 559
Opioid analgesia, 1
naloxone
non-opioid analgesia
prolyl-leucyl-glycinamide
snails
stress-induced analgesia
tyrosine-prolyl-leucyl-glycinamide
Opioid antagonist characterization, 657
A-18-F-NH_2
brain, bovine
F-8-F-NH_2
opioid antagonist distribution
radioimmunoassay
Opioid antagonist distribution, 657
A-18-F-NH_2
brain, bovine
F-8-F-NH_2
opioid antagonist characterization
radioimmunoassay
Opioid antagonist-like effects, 1173
brainstem
cardiovascular control
α-MSH
Opioid binding, 701
dynorphin A
in vitro

in vivo
Mu opioid binding sites, 1015
autoradiography
[^{125}I]FK33824
Opioid bladder effects, 625
in vivo
somatostatin analog
Opioid peptides
ATPase activity inhibition, 709
brain membranes, rat, 645
cardiac sarcolemma, 709
coronary pressure, 695
drug interactions, 709
isolated rat hearts, 695
morphine, 695, 709
naloxone, 695
opiate receptors, 645
radioimmunoassay, 645
Opioid receptors
analgesia, 613
intestinal transit, 613
kentsin, 613
lordosis, 309
ovariectomy, 309
ORG 2766
electrophysiology, 415
melanocortins, 415
nerve regeneration, 1057
route of administration, 1057
sciatic nerve damage, 1057
sciatic nerve regeneration, 415
Osmoregulation, 1003
dogs
thirst impairment
vasopressin antagonists
Ovariectomy
delta sleep-inducing peptide, 45
growth hormone release, 45
hypothalamus, 45
lordosis, 309
neuropeptide effects, 921
opioid receptors, 309
pituitary, 45
plasma LH levels, 921
Oxyntomodulin, 967
exocrine pancreatic secretion
glucagon
Oxytocin
footshock, 243
gastric motility, 505
hypothalamus, 505
paraventricular nucleus, 505
plasma levels, 243
spinal cord, 243
stimulatory effects, 505
thyrotropin releasing hormone, 505
vasopressin, 243
Oxytocin immunoreactivity, 7
pineal gland
vasopressin characterization
vasopressin-like peptides
Oxytocin levels, 411
dogs
lactation
suckling
vasoactive intestinal peptide levels
Oxytocin release, 807
goats
luteal regression
neurophysin secretion
Pain
analgesia, 191
cholinergic analgesia, 299
dynorphin, 191
human studies, cancer patients, 191
hypothermia, 299
intrathecal administration, 191
neuromodulatory effects, 299
swim analgesia, 299
thyrotropin-releasing hormone, 299
Pancreatic exocrine secretion, 973
bombesin
dogs
pancreatic polypeptide-antiserum
Pancreatic polypeptide
anterior pituitary gland, 539
avian feeding patterns, 585
chicks, 585
gonadotropin secretion, 539
narcolepsy, 585
neonatal exposure, 585
neuropeptide Y, 539
rats, males, 539
tonic-clonic convulsions, 585
Pancreatic polypeptide-antiserum, 973
bombesin
dogs
pancreatic exocrine secretion
Pancreatic polypeptide content, 165
guinea pig pancreatic polypeptide
pancreatic polypeptide structure
Pancreatic polypeptide structure, 165
guinea pig pancreatic polypeptide
pancreatic polypeptide content
Pancreatic secretion
cholecystokinin, 1023
corticotropin-releasing factor, 1011
dogs, 1011
gastric acid secretion, 575
gastric emptying, 1011
human corticotropin-releasing factor, 575
in vitro, 575
in vivo, 575
peptide/pseudo-peptide analogs, 1023
Parabrachial pontine complex, 267
monoamine components
neuropeptide components
Parathyroid hormone fragments, 443
arteriolar dilation
in vivo
muscarinic receptor stimulation
Paraventricular nucleus, 505
gastric motility
hypothalamus
oxytocin
stimulatory effects
thyrotropin releasing hormone
Parietal cells, 391
autoradiography
binding sites
chief cells
gastric mucosa
^{125}I-iodotyrosyl gastrin I
Pars intermedia, 69
background adaptation
brain, toads
melanophore stimulating hormone
melanophore stimulating hormone release
thyrotropin releasing hormone
Passive avoidance, 25
cholecystokinin octapeptide
footshock
proglumide
Peptide
A-18-F-NH_2, 657
adrenocorticotropic hormone, 819, 841
adrenocorticotropic hormone 1–24, 135
aminopeptidase M, 523
aminosuccyl, 791
angiotensin I, 135, 939
angiotensin II, 677, 737, 939
antisomatostatin, 619
arginine-vasopressin, 7, 385, 493, 785
arginine-vasotocin, 7
atrial natriuretic factor, 285, 449, 461
atrial natriuretic peptide, 257
atrial natriuretic polypeptide, 285
^{125}I-Bolton Hunter-cholecystokinin octapeptide, 109
bombesin, 127, 237, 423, 887, 973
bradykinin, 863
C-terminal glucopeptide, 757
caerulein, 109
calcitonin, 977
calcitonin gene-related peptide, 251, 399, 747, 1079
capsaicin, 399
carboxypeptidase B, 1035
ceruletide, 455
cholecystokinin, 153, 223, 645, 763, 769, 801, 911, 1023
cholecystokinin-26-32-NH_2, 109
cholecystokinin-33, 109
cholecystokinin octapeptide, 25, 109, 127, 267, 391, 651, 845
corticotropin-releasing factor, 135, 437, 819, 841, 927, 935, 1011
CRF, 1093
CTP, 625
cyclic Amp, 927
cyclo (Leu-Gly), 39
DAGO, 625
DPDPE, 625
delta sleep-inducing peptide, 45, 599
desglycinamide-arginine-vasopressin, 261
desglycinamide vasopressin, 785
dihydrosomatostatin, 849
dynorphin, 191, 559, 585, 837
dynorphin 1–9, 309
dynorphin 1–13, 811
dynorphin-A, 361, 367, 701
dynorphin-A(1–8), 645, 1075
dynorphin A (1–13), 1089
endorphin, 61
β-endorphin, 123, 309, 467, 605, 715, 819, 1119
α-neo-endorphin, 701
beta-endorphin-(1–27), 123
enkephalin, 103
Leu enkephalin, 251, 559, 695, 709, 837
Met-enkephalin, 113, 251, 267, 355, 487, 565, 609, 695, 709, 715, 1119
Met^5-enkephalin-Arg^6-Gly^7-Leu^8, 77, 645
(D-Ala^2,Met^5)-enkephalinamide, 113, 1029
epidermal growth factor, 347, 743, 877
17β estradiol, 997
F-8-F-NH_2, 657
[^{125}I]FK33824, 1015
FMRFamide, 533
follicle-stimulating hormone, 539

galanin, 921
gastric releasing peptide, 423
gastrin, 109
gastrin releasing peptide, 55
glucagon, 55, 967
glucagon-(1–21), 943
gonadotropin releasing hormone, 21, 543
Gln^8-gonadotropin-releasing hormone, 185
His^5,Trp^7,Tyr^8-gonadotropin releasing hormone, 185
gonadotropin releasing hormone associated peptide, 21
gonadotropin releasing prohormone, 335
growth hormone releasing factor, 199, 687
guinea pig pancreatic polypeptide, 165
human corticotropin-releasing factor, 575
human gastrin I, 391
^{125}I-daYFnLRFamide, 1065
interleukin-1, 501
kassinin, 169
kentsin, 613
luteinizing hormone, 539
luteinizing hormone-releasing hormone, 135
lysyl-bradykinin, 251
α-melanocyte-stimulating hormone, 581, 955
melanophore-stimulating hormone, 61, 69
^{131}I-methionine enkephalin, 899
MIF-1, 751, 997, 1051
morphiceptin, 309
α-MSH, 501, 1173
naloxone, 763
neo-kyotorphin, 905
neurokinin A, 169
neurokinin B, 169
neuromedin U 779
neuropeptide K, 921
neuropeptide Y, 61, 77, 145, 251, 539, 569, 585, 651, 823, 921, 1107
neurophysin, 807
neurophysin II, 267
neurotensin, 103, 127, 135, 195, 267, 639, 961, 1079
neurotensin (1–6), 135
neurotensin (1–8), 135
neurotensin (1–11), 135
neurotensin (8–13), 135
norleucine^4-NPY, 921
Org.2766, 581
oxyntomodulin, 967
oxytocin, 7, 243, 267, 411, 505, 807
pancreatic glucagon, 943
pancreatic polypeptide, 539, 585
pentagastrin, 89, 423
peptide F, 715
peptide histidine isoleucine, 13, 1101
peptide histidyl-isoleucine amide, 687
peptide YY, 823
physalaemin, 169
Pro-Leu-Gly, 1051
prolyl-leucyl-glycinamide, 1
L-prolyl-L-leucyl-glycinamide, 855
proopiomelanocortin, 61, 927
ψ[CH_2NH] pseudopeptide, 119
RC-102, 951
δ-receptor peptide, 309
sauvagine, 935, 1093
secretin, 633, 1011, 1101
serotonin, 267
small cardioactive peptide A, 179
SMS 201-995, 619
somatostatin, 77, 103, 135, 199, 251, 267, 619, 849, 869, 951, 1127
somatostatin 28(1–12), 207
spantide, 251
substance P, 13, 103, 127, 153, 169, 251, 267, 399, 947
^{125}I-substance P, 213
succinimide, 791
tetrodotoxin, 687
thyroid stimulating hormone, 743
thyrotropin releasing hormone, 69, 227, 231, 247, 291, 299, 319, 505, 543
thyrotropin-stimulating hormone, 539
trypsin, 1035
Tyr-MIF-1, 751, 1165
^{125}I-Tyr-MIF-1, 899
Tyr-Pro-Leu-Gly, 1051
tyrosine hydroxylase, 267
tyrosine-prolyl-leucyl-glycinamide, 1
urotensin I, 1093
vasoactive intestinal peptide, 893, 1101
vasoactive intestinal polypeptide, 13, 29, 35, 251, 267, 411, 477, 633, 663, 687, 743, 797
vasopressin, 243, 267, 763, 1003
vasotocin, 135
xenopsin, 135
YEYPS, 95
Peptide antisera
  brain, primate, 335
  central nervous system, 371
  cysteamine, 371
  GnRH-associated peptide, 335
  gonadotropin releasing prohormone, 335
  immunocytochemistry, 335
  immunohistochemistry, 371
  immunostaining, 335
  somatostatin-like immunoreactivity, 371
Peptide chemical characterization, 663
  enzymatic radioiodination
  peptide purification
Peptide comparisons
  cats, 423
  gastric releasing peptide, 423
  gastric secretion, 423
  guinea pig ileum, 169
  motility, 423
  neurokinins, 169
  rat duodenum, 169
  smooth muscle contraction, 169
  structure-activity relationship, 169
  substance P, 169
  tackykinins, 169
Peptide distribution, 543
  anterior pituitary
  gonadotropin releasing hormone
  immunoreactivity
  long-term primary cultures
  thyrotropin releasing hormone
Peptide immunoreactivity, 77
  brain, human
  co-localization
  Met-enkephalin-Arg^6-Gly^7-Leu^8
  neuropeptide Y
  pheochromocytomas
  somatostatin
Peptide/pseudo-peptide analogs, 1023
  cholecystokinin
  pancreatic secretion
Peptide purification, 663
  enzymatic radioiodination
  peptide chemical characterization
Peptide release
  anterior pituitary, 367
  anterior pituitary, bovine, 361
  dynorphin-A, 361, 367
  17β-estradiol, 367
  immunoreactivity, 361, 367
  in vitro, 361, 367
  in vivo, 361, 367
  molecular weight, 361, 367
  sheep, 367
Peptide sequencing, 179
  Aplysia
  precursor processing
  purification
  small cardioactive peptide A
Peptide synthesis, 119
  ψ[CH_2NH] pseudopeptide, 119
Peptide, YY, 823
  chicks
  eating
  intracerebroventricular injection
  neuropeptide Y
Pharmacological examination, 127
  cholecystokinin-octapeptide
  contractile activity
  in vitro
  pylorus
Phenethanol N-methyltransferase, 437
  adrenal medulla
  corticotropin-releasing factor
  dopamine beta-hydroxylase
  plasma corticosterone
  route of administration
Pheochromocytomas, 77
  brain, human
  co-localization
  Met-enkephalin-Arg^6-Gly^7-Leu^8
  neuropeptide Y
  peptide immunoreactivity
  somatostatin
Pigment dispersion, 955
  calcium
  melanophore response
Pineal gland, 7
  oxytocin immunoreactivity
  vasopressin characterization
  vasopressin-like peptides
Pituitary
  antiserum specificity, 135
  delta sleep-inducing peptide, 45
  fishes, bony, 135
  growth hormone release, 45
  hypothalamus, 45, 135
  immunoreactivity, 135
  neurotensin, 135
  ovariectomy, 45
Pituitary protein, 593
  Alzheimer's disease
  cerebrospinal fluid
  human plasma
PLG analogs, 855
  down regulation
  haloperidol

striatal dopamine receptor
supersensitivity
Plasma, 939
angiotensin I
angiotensin, II
cerebrospinal fluid
dogs
high performance liquid chromatography
Plasma corticosterone, 437
adrenal medulla
corticotropin-releasing factor
dopamine beta-hydroxylase
phenethanol N-methyltransferase
route of administration
Plasma cortisol levels, 715
heat acclimation
human studies
plasma peptide responses
Plasma, human, 599
aggregation
degradation
delta sleep-inducing peptide
delta sleep-inducing peptide analogues
plasma, rat
Plasma LH levels
gonadectomy, 721
LHRH-immunopositive neurons, 721
neuropeptide effects, 921
ovariectomy, 921
Plasma levels, 243
footshock
oxytocin
spinal cord
vasopressin
Plasma peptide responses, 715
heat acclimation
human studies
plasma cortisol levels
Plasma, rat, 599
aggregation
degradation
delta sleep-inducing peptide
delta sleep-inducing peptide analogues
plasma, human
Plasminogen activator activity, tissue type, 29
cumulus-oocyte complexes
granulose cells
plasminogen activator activity, urinary type
vasoactive intestinal peptide
Plasminogen activator activity, urinary type, 29
cumulus-oocyte complexes
granulose cells
plasminogen activator activity, tissue type
vasoactive intestinal peptide
POMC gene expression, 927
cyclic AMP
corticotropin releasing factor
tumor cells
Porcine ileal mucosa, 639
molecular heterogeneity
neurotensin-like immunoreactivity
Post-synaptic potentials, 565
dorsal root ganglia
Met-enkephalin
spinal root ganglia
Posterior hypophysis, 461
atrial natriuretic factor
biological activity
immunoreactivity
Posterior pituitary, amphibian, 1119
β-endorphin
Met-enkephalin
radioimmunoassay
Postnatal development, 983
rabbits
somatostatin binding sites
somatostatin levels
Precursor processing, 179
Aplysia
peptide sequencing
purification
small cardioactive peptide A
Prenatal administration, 493
arginine vasopressin
memory retrieval
sexual dimorphism
Pressor effects, 863
bradykinin
dose-dependent effects
epicardial application
guinea pigs
tachycardia
ProCCK flanking peptide, 95
cholecystokinin precursor
immunohistochemistry studies
radioimmunoassay studies
rat gut
Processing enzymes, 21
gonadotropin releasing hormone
gonadotropin releasing hormone associated peptide
substrate specificity
Proglumide
cerebral ischemia, 769
cholecystokinin, 769
cholecystokinin octapeptide, 25
footshock, 25
gerbils, 769
passive avoidance, 25
stroke index score, 769
Pro-Leu-Gly, 1051
in vivo
MIF-1
striatal dopamine receptor binding
tolerance
Tyr-Pro-Leu-Gly
Prolyl-leucyl-glycinamide, 1
naloxone
non-opioid analgesia
opioid analgesia
snails
stress-induced analgesia
tyrosine-prolyl-leucyl-glycinamide
Prostaglandin-stimulated intestinal fluid, 1029
CNS-mediated inhibition
[D-Ala², Met⁵]-enkephalinamide
ion transport
ψ[CH_2NH] Pseudopeptide, 119
peptide synthesis
Pulmonary arterial pressure, 285
angina pectoris
atrial natriuretic factor
atrial natriuretic polypeptide
cardiac output
hemodynamic variables
human studies
Pulmonary endocrine cells, 977
calcitonin
in vitro
Purification, 179
Aplysia
peptide sequencing
precursor processing
small cardioactive peptide A
Purified synaptosomal plasma membranes, 467
β-endorphin metabolism
ethanol
Pylorus, 127
cholecystokinin-octapeptide
contractile activity
in vitro
pharmacological examination

Quaternary structure, 773
aminoterminal CNBr fragments
catalytic activity
lactate dehydrogenase isoenzymes
reactivation agonists
reversed-phase HPLC

Rabbits
endogenous antipyretic response, 501
febrile response, 501
α-melanocyte stimulating hormone, 501
postnatal development, 983
salivary gland, 13
somatostatin binding sites, 983
somatostatin levels, 983
vasoactive intestinal polypeptide, 13
vasodilatation, 13
Radioimmunoassay
A-18-F-NH_2, 657
brain, bovine, 657
brain membranes, rat, 645
cholecystokinin precursor, 95
β-endorphin, 1119
F-8-F-NH_2, 657
histamine, 473
immunohistochemistry studies, 95
in vitro, 473
Met-enkephalin, 1119
opiate receptors, 645
opioid antagonist characterization, 657
opioid antagonist distribution, 657
opioid peptides, 645
posterior pituitary, amphibian, 1119
proCCK flanking peptide, 95
rat gut, 95
stomach, rat, 473
thyrotropin-releasing hormone release, 473
Radioligand binding study, 477
arteries, rat/bovine comparisons
coronary artery
mesenteric artery
vasoactive intestinal receptors
Radioreceptor assay, 1065
FMRFamide receptors
Helix neurons
Rat duodenum, 169
guinea pig ileum
neurokinins
peptide comparisons
smooth muscle contraction
structure-activity relationship
substance P

tachykinins
Rat gut, 95
cholecystokinin precursor
immunohistochemistry studies
proCCK flanking peptide
radioimmunoassay studies
Rat/mice comparisons, 841
adrenocorticotropic hormone
corticotropin-releasing factor
grooming
Rats, conscious, 747
calcitonin gene-related peptide
renal blood flow
vasodilation
Rats, males, 539
anterior pituitary gland
gonadotropin secretion
neuropeptide Y
pancreatic polypeptide
Rats, spontaneously hypertensive, 227
blood pressure
body temperature
hypertension
hyperthermia
supersensitivity
thyrotropin releasing hormone
RC-102, 951
human studies
immunomodulation
leukocyte migration inhibiting factor
somatostatin
Reactivation agonists, 773
aminoterminal CNBr fragments
catalytic activity
lactate dehydrogenase isoenzymes
reversed-phase HPLC
quaternary structure
Receptor binding, 877
biological potency
epidermal growth factor
mitogenesis
N-terminal heterogenecity
Receptor distribution, 231
age differences
hypertension
strain differences
thyrotropin-releasing hormone
Receptor modulation, 319
[^{3}H]apomorphine binding
dopamine receptors
in vitro
receptor-receptor interaction
[^{3}H]spiperone binding
thyrotropin-releasing hormone
Receptor-receptor interaction, 319
[^{3}H]apomorphine binding
dopamine receptors
in vitro
receptor modulation
[^{3}H]spiperone binding
thyrotropin-releasing hormone
Receptor selectivity, 811
analgesia
diuresis
dynorphin analog
Reciprocal response, 487
dopamine neurotransmission
Met-enkephalin
striatum
Region-specific antibodies, 801
cholecystokinin
gastrectomy
human studies
Regional distribution, 291
basal conditions
in vitro release
stimulated conditions
thyrotropin-releasing hormone
Renal blood flow, 747
calcitonin gene-related peptide
rats, conscious
vasodilation
Renal functions, 961
C-terminals
neurotensin metabolism
N-terminals
Respiration, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
schizophrenia
sex
social behavior
stress
stroke
temperature
tolerance
Retinal, 1
Retinol, 1
Reversed-phase HPLC, 773
aminoterminal CNBr fragments
catalytic activity
lactate dehydrogenase isoenzymes
reactivation agonists
quaternary structure
Right atrial pressure, 257
atrial natriuretic peptide
in situ retrograde perfused heart
vagotomy, bilateral
volume expansion
Route of administration
adrenal medulla, 437
corticotropin-releasing factor, 437
dopamine beta-hydroxylase, 437
nerve regeneration, 1057
Org 2766, 1057
phenethanol N-methyltransferase, 437
plasma corticosterone, 437
sciatic nerve damage, 1057

Salivary gland, 13
rabbits
vasoactive intestinal polypeptide
vasodilatation
Satiety, 943
glucagon-(1–21)
spasmolysis
Sauvagine, 935
aggression
corticotropin releasing factor
isolation
social behavior
Schizophrenia, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
sex
social behavior
stress
stroke
temperature
tolerance
Sciatic nerve damage, 1057
nerve regeneration
Org 2766
route of administration
Sciatic nerve regeneration, 415
electrophysiology
melanocortins
ORG.2766
Secretin receptors, 633
cyclic AMP
guinea pig pancreatic acini
vasoactive intestinal peptide receptors
Secretion regulation, 61
amphibians
melanophore-stimulating hormone
neuropeptide Y
Sensory neurons, 399
calcitonin gene-related peptide
capsaicin
immunoreactivity
substance P
Septum, 385
arginine vasopressin
body temperature
brain, rabbit
fever
vasopressin antiserum
Sex, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenic
social behavior
stress
stroke
temperature
tolerance
Sex differences, 845
cholecystokinin octapeptide
food intake
obesity
water intake
Sexual dimorphism, 493
arginine vasopressin
memory retrieval
prenatal administration

Sheep, 367
anterior pituitary
dynorphin-A
17β-estradiol
immunoreactivity
in vitro
in vivo
molecular weight
peptide release
Sheep pituitary, 1045
N-acetylated endorphins
anterior pituitary
neurointermediate lobe
Sleep deprivation, 175
energy deficiency
exercise
human study
VIP plasma levels
Small cardioactive peptide A, 179
Aplysia
peptide sequencing
precursor processing
purification
Small cell lung cancer cells, 109
cholecystokinin
high affinity binding sites
Smooth muscle contraction, 169
guinea pig ileum
neurokinins
peptide comparisons
rat duodenum
structure-activity relationship
substance P
tachykinins
Snails
FMRFamide, 515, 533
FMRFamide-like peptides, 515
FMRF-related heptapeptides, 533
naloxone, 1
non-opioid analgesia, 1
opioid analgesia, 1
prolyl-leucyl-glycinamide, 1
stress-induced analgesia, 1
tyrosine-prolyl-leucyl-glycinamide, 1
Social behavior
activity, 1135
aggression, 935
alcohol, 1135
cardiovascular responses, 1135
corticotropin releasing factor, 935
dependence, 1135
drinking, 1135
eating, 1135
endogenous opiates, review, 1135
epilepsy, 1135
immune system, 1135
isolation, 935
learning, 1135
memory, 1135
mental illness, 1135
respiration, 1135
sauvagine, 935
schizophrenia, 1135
sex, 1135
stress, 1135
stroke, 1135
temperature, 1135
tolerance, 1135
Somatostatin
anterior pituitary, 199
brain, human, 77
co-localization, 77
cyclic AMP, 199
desensitization, 199
dogs, 619
electrolytes, 619
Met-enkephalin-Arg^6-Gly^7-Leu^8, 77
growth hormone, 199, 1127
growth hormone-releasing factor, 199
human studies, 951
immunocytochemistry, 1127
immunomodulation, 951
intestinal absorption, 619
leukocyte migration inhibiting factor, 951
Met-enkephalin-Arg^6-gly^7-Leu^8, 77
morphine antagonism, 869
neuropeptide Y, 77
octapeptide analogs, 869
opiate binding, 869
peptide immunoreactivity, 77
pheochromocytomas, 77
RC-102, 951
strain differences, 1127
Somatostatin 28(1–12), 207
human medullary thyroid carcinoma cell line
Somatostatin analog, 625
in vivo
opioid bladder effects
Somatostatin binding sites, 983
postnatal development
rabbits
somatostatin levels
Somatostatin levels, 983
postnatal development
rabbits
somatostatin binding sites
Somatostatin-like immunoreactivity
central nervous system, 371
cysteamine, 371
dihydrosomatostatin, 849
guinea pig brains, 849
immunohistochemistry, 371
peptide antisera, 371
Spasmolysis, 943
glucagon-(1–21)
satiety
Spinal cord
cholecystokinin, 153
flexion reflex, 153
footshock, 243
intrathecal administration, 213
label distribution, 213
morphine, 153
nociception, 153
oxytocin, 243
plasma levels, 243
substance P, 153
^{125}I-substance P, 213
thyrotropin releasing hormone, 247
traumatic injury, 247
vasopressin, 243
Spinal cord cultures, 565
dorsal root ganglia
Met-enkephalin
post-synaptic potentials
Spinal cord neurons, 559
mouse cell cultures
opiate receptors
[^{3}H]Spiperone binding, 319
[^{3}H]apomorphine binding
dopamine receptors
in vitro
receptor modulation
receptor-receptor interaction
thyrotropin-releasing hormone
Spleen, 737
angiotensin II binding
autoradiography
Stereotypy, drug induced, 39
conditioned avoidance
cyclo (Leu-Gly)
dopamine receptors
haloperidol
lesions, 6-hydroxydopamine
Stimulated conditions, 291
basal conditions
in vitro release
regional distribution
thyrotropin-releasing hormone
Stimulatory effects, 505
gastric motility
hypothalamus
oxytocin
paraventricular nucleus
thyrotropin releasing hormone
Stomach, rat, 473
histamine
in vitro
radioimmunoassay
thyrotropin-releasing hormone release
Strain differences
age differences, 231
growth hormone, 1127
hypertension, 231
immunocytochemistry, 1127
receptor distribution, 231
somatostatin, 1127
thyrotropin-releasing hormone, 231
Stress
activity, 1135
alcohol, 1135
analgesia, 355
brain Met-enkephalin content, 355
cardiovascular responses, 1135
dependence, 1135
drinking, 1135
eating, 1135
endogenous opiates, review, 1135
epilepsy, 1135
immune system, 1135
learning, 1135
memory, 1135
respiration, 1135
schizophrenia, 1135
sex, 1135
social behavior, 1135
stroke, 1135
temperature, 1135
tolerance, 1135
Stress-induced analgesia, 1
naloxone
non-opioid analgesia
opioid analgesia
prolyl-leucyl-glycinamide
snails
tyrosine-prolyl-leucyl-glycinamide
Striatal dopamine receptor, 855
down regulation
haloperidol
PLG analogs
supersensitivity
Striatal dopamine receptor binding, 1051
in vivo
MIF-1
Pro-Leu-Gly

tolerance
Tyr-Pro-Leu-Gly
Striatum, 487
dopamine neurotransmission
Met-enkephalin
reciprocal response
Stroke, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
temperature
tolerance
Stroke index score, 769
cerebral ischemia
cholecystokinin
gerbils
proglumide
Structure-activity relationship
dynorphin-induced circling, 837
guinea pig ileum, 169
in vivo, 837
motor control, 837
neurokinins, 169
peptide comparisons, 169
rat duodenum, 169
smooth muscle contraction, 169
substance P, 169
substantia pars reticulata, 837
tachykinins, 169
Structural specificity, 687
neuron development
neuronal cell death
neuronal survival
Substance P
binding sites, 947
calcitonin gene-related peptide, 399
capsaicin, 399
cholecystokinin, 153
flexion reflex, 153
guinea pig ileum, 169
human fetus, 947
immunoreactivity, 399
morphine, 153
neurokinins, 169
nociception, 153
peptide comparisons, 169
rat duodenum, 169
sensory neurons, 399
smooth muscle contraction, 169
spinal cord, 153
structure-activity relationship, 169
tachykinins, 169
^{125}I-Substance P, 213
intrathecal administration
label distribution
spinal cord
Substantia pars reticulata, 837
dynorphin-induced circling
in vivo
motor control
structure-activity relationship
Substrate specificity, 21
gonadotropin releasing hormone
gonadotropin releasing hormone associated peptide
processing enzymes
Suckling, 411
dogs
lactation
oxytocin levels
vasoactive intestinal peptide levels
Supersensitivity
blood pressure, 227
body temperature, 227
down regulation, 855
haloperidol, 855
hypertension, 227
hyperthermia, 227
PLG analogs, 855
rats, spontaneously hypertensive, 227
striatal dopamine receptor, 855
thyrotropin releasing hormone, 227
Swim analgesia, 299
cholinergic analgesia
hypothermia
neuromodulatory effects
pain
thyrotropin-releasing hormone
Sympathetic preganglionic neurons, 103
cats
coexistence
neuropeptides
Synaptosomal membranes, brain, 195
fundus plasma membranes
neurotensin receptors
target size analysis

Tachycardia, 863
bradykinin
dose-dependent effects
epicardial application
guinea pigs
pressor effects
Tachykinins, 169
guinea pig ileum
neurokinins
peptide comparisons
rat duodenum
smooth muscle contraction
structure-activity relationship
substance P
Target size analysis, 195
fundus plasma membranes
neurotensin receptors
synaptosomal membranes, brain
Temperature, 1135
activity
alcohol
cardiovascular responses
dependence
drinking
eating
endogenous opiates, review
epilepsy
immune system
learning
memory
mental illness
respiration
schizophrenia
sex
social behavior
stress
stroke
tolerance
Thirst impairment, 1003
dogs
osmoregulation
vasopressin antagonists
[^{3}H]-Thymidine, 347
circadian patterns
DNA synthesis
epidermal growth factor
fasting
Thyroid cultures, human, 893
carbamylcholine
cholinergic receptors
vasoactive intestinal peptide
Thyroid hormone secretion, 743
epidermal growth factor
Thyrotropin-releasing hormone
age differences, 231
anterior pituitary, 543
[^{3}H]apomorphine binding, 319
background adaptation, 69
basal conditions, 291
blood pressure, 227
body temperature, 227
brain, toads, 69
cholinergic analgesia, 299
dopamine receptors, 319
gastric motility, 505
gonadotropin releasing hormone, 543
hypertension, 231, 227
hyperthermia, 227
hypothalamus, 505
hypothermia, 299
immunoreactivity, 543
in vitro, 319
in vitro release, 291
long-term primary cultures, 543
melanophore stimulating hormone, 69
melanophore stimulating hormone release, 69
neuromodulatory effects, 299
oxytocin, 505
pain, 299
paraventricular nucleus, 505
pars intermedia, 69
peptide distribution, 543
rats, spontaneously hypertensive, 227
receptor distribution, 231
receptor modulation, 319
receptor-receptor interaction, 319
regional distribution, 291
spinal cord, 247
[^{3}H]spiperone binding, 319
stimulated conditions, 291
stimulatory effects, 505
strain differences, 231
supersensitivity, 227
swim analgesia, 299
traumatic injury, 247
Thyrotropin-releasing hormone release, 473
Tolerance
activity, 1135
alcohol, 1135
cardiovascular responses, 1135
dependence, 1135
drinking, 1135

eating, 1135
endogenous opiates, review, 1135
epilepsy, 1135
immune system, 1135
in vivo, 1051
learning, 1135
memory, 1135
mental illness, 1135
MIF-1, 1051
Pro-Leu-Gly, 1051
respiration, 1135
schizophrenia, 1135
sex, 1135
social behavior, 1135
stress, 1135
striatal dopamine receptor binding, 1051
stroke, 1135
temperature, 1135
Tonic-clonic convulsions, 585
avian feeding patterns
chicks
narcolepsy
neonatal exposure
pancreatic polypeptides
Transport system, 899
blood-brain barrier
methionine enkephalin
Tyr-MIF-1
Traumatic injury, 247
spinal cord
thyrotropin releasing hormone
Tumor cells, 927
cyclic AMP
corticotropin releasing factor
POMC gene expression
Tyr-MIF-1
γ-aminobutyric acid, 751
benzodiazepine receptor binding, 751
blood-brain barrier, 899
human lymphocytes, 1165
methionine enkephalin, 899
MIF-1, 751
morphine, 1165
naloxone, 1165
transport system, 899
Tyrosine hydroxylase, 49
γ-butyrolactone-γ-carbonyl-histidyl-prolinamide
dopaminergic neuron
mesocortical system
mesolimbic system
nigrostriatal system
Tyrosine-prolyl-leucyl-glycinamide, 1
naloxone
non-opioid analgesia
opioid analgesia
prolyl-leucyl-glycinamide
snails
stress-induced analgesia
Tyr-Pro-Leu-Gly, 1051
in vivo
MIF-1
Pro-Leu-Gly
striatal dopamine receptor binding
tolerance

Ultraviolet spectrometry, 791
aminosuccinyl residue identification
Underlying white matter, 1107
immunocytochemistry
neuropeptide Y immunoreactivity
visual cortex, human
Uterus, 1169
high affinity binding
[^{3}H]neurotensin

Vaginal blood flow, 797
human studies, women
vaginal blood flow
vaginal lubrication
vasoactive intestinal polypeptide
Vaginal lubrication, 797
human studies, women
vaginal blood flow
vasoactive intestinal polypeptide
Vagotomy, bilateral, 257
atrial natriuretic peptide
in situ retrograde perfused heart
right atrial pressure
volume expansion
Vasoactive intestinal peptide
carbamylcholine, 893
cholinergic receptors, 893
cumulus-oocyte complexes, 29
granulose cells, 29
growth hormone secretion, 35
in vitro, 35
in vivo, 35
lesions, mediobasal hypothalamus, 35
plasminogen activator activity, tissue type, 29
plasminogen activator activity, urinary type, 29
rabbits, 13
salivary gland, 13
thyroid cultures, human, 893
vasodilatation, 13
Vasoactive intestinal peptide levels
dogs, 411
energy deficiency, 175
exercise, 175
human study, 175
lactation, 411
oxytocin levels, 411
sleep deprivation, 175
suckling, 411
Vasoactive intestinal peptide receptors
arteries, rat/bovine comparisons, 477
coronary artery, 477
cyclic AMP, 633
guinea pig pancreatic acini, 633
high affinity binding, 1101
lung cancer cells, 1101
mesenteric artery, 477
radioligand binding, 477
secretin receptors, 633
Vasoactive intestinal polypeptide, 797
human studies, women
vaginal blood flow
vaginal lubrication

Vasodilation
calcitonin gene-related peptide, 747
rabbits, 13
rats, conscious, 747
renal blood flow, 747
salivary gland, 13
vasoactive intestinal polypeptide, 13
Vasopressin, 243
footshock
oxytocin
plasma levels
spinal cord
Vasopressin antagonists, 1003
dogs
osmoregulation
thirst impairment
Vasopressin antiserum, 385
arginine vasopressin
body temperature
brain, rabbit
fever
septum
Vasopressin characterization, 7
oxytocin immunoreactivity
pineal gland
vasopressin-like peptides
Vasopressin deficiency, 763
cholecystokinin
drinking
eating
naloxone
Vasopressin-like peptides, 7
oxytocin immunoreactivity
pineal gland
vasopressin characterization
Vasopressin secretion, 449
atrial natriuretic factor
hypothalamic action
Visual cortex, human, 1107
immunocytochemistry
neuropeptide Y immunoreactivity
underlying white matter
Volume expansion, 257
atrial natriuretic peptide
in situ retrograde perfused heart
right atrial pressure
vagotomy, bilateral

Water consumption
central control, 651
cholecystokinin octapeptide, 651, 845
dogs, 651
food intake, 651, 845
obesity, 845
sex differences, 845

Xenopus laevis, 1093
in vitro
MSH release regulation
neurointermediate lobe

AUTHOR INDEX

Aboukhair, N., 523
Aguila, M. C., 449
Ahmad, S., 195
Ahrén, B., 55, 743
Akil, H., 701, 811
Alberetto, M., 455
Alexsavich, B., 721
Andrews, P. C., 207
Antunes-Rodrigues, J., 449
Appia, F., 89
Arch, S., 829
Arilla, E., 983
Armstrong, L. E., 715
Aron, D. C., 207
Atkins, S. T., 869
Ayres, E. A., 613

Baba, S., 651
Bachelard, H., 863, 1079
Bado, A., 89
Baker, A. E., 877
Balasubramanian, A., 921
Baldrighi, G., 811
Banks, W. A., 899
Bansinath, M., 227, 231
Barabé, J., 863
Bataille, D., 967
Batten, T. F. C., 135
Bean, A. J., 39
Becker, K. L., 977
Beckman, A. L., 247
Beckwith, B. E., 493
Bell, R. E., 501
Bennett, C. D., 877
Bernard, C., 423
Bernardi, P., 695, 709
Berridge, C. W., 841
Bhargava, H. N., 227, 231, 1051
Biedzinski, T. M., 967
Bilski, J., 575
Bishop, J. F., 927
Blake, C. A., 539
Block, C. H., 267
Blomquist, L., 13
Bloom, S. R., 779
Bluet-Pajot, M. T., 35
Bodnar, R. J., 299
Bowen, W. D., 811, 869
Brandi, M. L., 893
Brenneman, D. E., 687
Bridges, T. E., 385
Broekkamp, C. L. E., 1057
Brosnihan, K. B., 939
Brown, D. R., 1029
Brownstein, M., 371
Bruns, C., 829
Bueno, L., 619
Buijs, R. M., 243
Burbach, J. P. H., 757
Burbach, P. H., 7
Burks, T. F., 613
Butler, P. D., 299

Cabib, S., 935
Caldarera, C. M., 695, 709
Calderara, A., 455
Cantin, M., 461
Capasso, S., 791
Carney, D. N., 1101
Carter, D. A., 1173
Castrén, E., 737
Cavagnini, F., 455
Ceccatelli, S., 371
Chan, J. S. D., 593
Chao, C. C., 361, 367
Chappell, M. C., 939
Charli, J.-L., 291
Chaya, M., 473
Chayvialle, J. A., 423
Cheng, M. C., 1045
Cherkin, A., 585
Chi, D. S., 1165
Chicau-Chovet, M., 89
Childs, G. V., 543
Chiu, P., 997
Chiu, S., 855, 997
Chohan, P., 779
Chowdhury, P., 1061
Chrétien, M., 593
Cisneros, M., 291
Clements, J. A., 1045
Cobb, C. G., 533
Collinet, M., 423
Cooper, D. M., 39
Coy, D. H., 119, 811, 869
Cridland, R. A., 213
Crine, A. F., 243
Crowley, W. R., 921
Cruijsen, P. M. J. M., 1093
Cuber, J. C., 423
Culling-Berglund, A. J., 467
Dahl, K. D., 29
Dalgaard, D., 797
Damassa, D. A., 721
Danesi, L., 455
Danger, J.-M., 61
Daniel, E. E., 195
Danks, J. A., 645
Das, S., 227, 231
Davis, T. P., 467
Davison, B. A., 823
Debas, H. T., 1011
Debinski, W., 461
De Jong, A. J. L., 973
Dekker, A. J. A. M., 1057
De Koning, P., 415
De Leede, L. G. J., 1057
Dembinski, A., 575
Demura, H., 285
De Nijs, H., 1057
De Paolis, C., 455
Deupree, D., 25
Devaux, M. A., 967
Dings, A., 1093
Dinh, T. T., 677
Döbeli, H., 773
Doble, K. E., 515, 533
Dockray, G. J., 95
Domin, J., 779
Dores, R. M., 1119
Douglass, L. W., 823
Dowe, J. P., 443
Du, L. F., 769
Dubrasquet, M., 89
Dunn, A. J., 841
Durand, D., 35
Duranti, R., 153
Dvorská, I., 785

Ebberink, R. H. M., 515
Edwall, B., 13
Edwards, P. M., 581
Elde, R., 371
Elgin, R. J., Jr., 39
Ellinwood, W. E., 159
Eng, J., 165
Englin, I., 961
Eriksson, M., 411

Fahrenkrug, J., 797
Farah, J. M., 927
Farina, R., 455
Fazekas, Á., 13
Feng, J., 501
Ferrario, C. M., 939
Fischer, J. A., 399
Fischman, A. J., 819
Foster, G. A., 687
Fox, D. A. 613
Franco-Cereceda, A., 399
Friederich, D. P., 837
Friederich, M. W., 837
Fujikawa, D. G., 585
Fukamachi, Y., 257
Fukata, J., 1075
Funatsu, K. S., 319
Funder, J. W., 1045

Garcia, R., 461
Gardner, J. D., 633
Gauthier, S., 213
Gazelius, B., 13
Ge, M., 905
Geary, N., 943
Genest, J., 461
George, S. R., 487
Geraerts, W. P. M., 515
Ghatei, M. A., 779
Gianlupi, A., 605
Gibbs, J., 127
Giles, T. D., 609
Gillespie, T. J., 467
Gillessen, D., 773
Gispen, W. H., 415, 581
Glatt, C. E., 1089
Goldman, S., 1107
Goldsmith, P. C., 335
Gorzalka, B. B., 309
Graf, M. V., 599
Greenberg, M. J., 515, 533
Grover, A. K., 195
Gu, X., 769
Gutkowska, J., 461

Hallman, H., 371
Hardy, K. J., 961
Harris, R. B., 21
Hashimoto, K., 113
Hattori, T., 113
Hemstreet, M. K., 869
Henke, H., 399
Henry, J. L., 213
Herkenham, M., 1015
Hermann, G. E., 505
Hersh, L. B., 523
Hesketh, D., 989
Hirofuji, E., 247
Hirooka, Y., 473
Hirosawa, K., 285
Ho, W. K. K., 191
Hoffman, G. E., 267, 1127
Hoke, W. S., 347
Hökfelt, T., 371, 399
Holaday, J. W., 1089
Holder, M. D., 763
Homeida, A. M., 807
Honda, T., 285
Hosotani, R., 1061
Hosta, L. P., 207
Houdi, A. A., 1035
Houghten, R., 701
Hrbas, P., 785
Hruby, V. J., 625
Hsiao, S., 25
Hsueh, A. J. W., 29
Hu, H., 327, 569
Hu[illegible]g, C.-G., 165
Hu[illegible], M., 477
Hub[illegible]ard, R. W., 715
Hulmes, J. D., 165
Hurni, W. M., 877

Iadarola, M. J., 645
Iguchi, H., 593
Imura, H., 77, 1075
Inagami, T., 285
Inanaga, K., 49, 319
Inoue, H., 113
Inoue, T., 651
Inui, A., 651
Iyer, K. S., 45
Izquierdo, I., 605

Jach, H., 185
Jacobowitz, D. M., 539
Jacobson, A. E., 1015
Jansen, J. B. M. J., 801
Jaworek, J., 575
Jayaraman, A., 327, 569
Jenks, B. G., 61, 69, 1093
Jennekens, F. G. I., 581
Jensen, R. T., 633
Jia, M., 559, 565
Johnson, R. L., 855, 997
Jolkkonen, J., 261
Jonsson, A.-C., 95
Joseph-Bravo, P., 291
Joshua, I. G., 443
Jung, C. Y., 195

Kabayama, Y., 257
Kageyama, J., 113
Kalra, S. P., 921
Kamisaki, T., 257
Kaneko, K., 391
Kasson, B. G., 29
Kastin, A. J., 751, 899, 1135, 1165
Kavaliers, M., 1
Kazmierski, W., 625
Kenner, J. R., 1089
Kertesz, M., 487
Khorram, O., 159
King, J. A., 185
King, J. C., 721
Kline, J. K., 533
Knight, P. B., 247
Knight, R. M., 927
Komatsu, H., 391
Konecka, A. M., 431

Konturek, S. J., 575
Kordon, C., 35
Korman, L. Y., 1101
Kozłowski, S., 1003
Kraemer, W. J., 715
Krukoff, T. L., 109
Kubo, K., 169
Kuchel, O., 461
Kuenzel, W. J., 823
Kugel, G., 721
Kupfermann, I., 179
Kurihara, M., 737
Kurumaji, A., 355
Kwan, C. Y., 195
Kyrkouli, S. E., 237

Labrie, F., 199
Lai, Y. I., 841
Lamers, C. B. H. W., 801, 973
Lappe, R. W., 747
Lát, J., 785
Lebovic, G. S., 1101
Lecomte, J. M., 89
Lederis, K., 385, 663
Lee, K. J., 493
Lefèvre, G., 199
Legros, J.-J., 261
Leibowitz, S. F., 237
Lemay, J., 947
Leonard, J.-F., 35
Lergier, W., 773
Leva, N., 715
Li, C. H., 123
Lightman, S. L., 1173
Lima, L., 437
Lindén, A., 411
Linnoila, R. I., 977
Lipkowski, A. W., 431
Lipton, J. M., 501
Liu, B., 7
Liu, F., 769
Liu, Y.-X., 29
Llados-Eckman, C., 247
Lloyd, P. E., 179
Long, J. B., 1089
Lopez-Ruiz, M. P., 983
Lotstra, F., 911
Lucas, A. M., 955
Lui, G., 613
Lundberg, J. M., 13, 399

McCann, S. M., 45
McDonald, J. K., 145
McDonald, T. J., 423
McKay, D., 1061
McMaster, D., 663

Magella, A., 455
Magnan, J., 947
Majane, E. A., 657
Malkinson, T. J., 385
Malven, P. V., 361, 367
Marchitelli, L. J., 715
Marivoet, S., 135
Martin, G. E., 39
Martinez, J., 1023
Martinovic, J., 449
Matsumoto, T., 49
May, V., 543
Mehal, Z. D., 191
Melchiorri, P., 935
Mele, A., 935
Mendez, M., 291
Michals, E. A., 899
Millar, R. P., 185
Miller, L. G., 751
Mishra, R. K., 855, 989, 997
Mitsuma, T., 473
Mochizuki, T., 575
Moldow, R. L., 819
Molloy, S., 829
Moody, T. W., 103, 1101
Morency, M. A., 989
Morioka, H., 651
Morley, J. E., 585
Mounier, F., 35
Munekata, E., 169
Murphy, R. B., 127
Muscari, C., 695, 709
Mutt, V., 423
Mycroft, F. J., 1051

Naas, F., 855
Nagain, C., 1023
Nakahara, T., 49
Nakai, Y., 1075
Nakaishi, S., 1075
Nakamura, M., 391
Naruse, K., 285
Naruse, M., 285
Nelson, P. G., 559, 565
Netto, C. A., 605
Nielsen, J., 797
Nikolics, K., 335
Nobin, A., 251
Nogimori, T., 473
Norris, M., 449
Nunan, L., 625
Nylander, I., 371
Nylen, E. S., 977

Obana, K., 285
Oda, M., 391
O'Donohue, T. L., 927
Ohtake, K., 473
Oliff, A., 877
Oliveira, C. B., 605
Oliverio, A., 935
Olson, G. A., 1135
Olson, R. D., 1135
Ong, B. H., 191
Ono, N., 113
Opstad, P. K., 175
Osakada, F., 169
Osamura, R. Y., 77
Ota, Z., 113
Ottesen, B., 797
Owman, Ch., 251
Oya, M., 651

Palen, T. E., 21
Pan, Y.-C. E., 165
Pappas, T. N., 1011
Pawlikowski, M., 951
Payza, K., 1065
Pedersen, B., 797
Pedersen, J. H., 639
Pelletier, G., 61, 1107
Petermann, J. B., 399
Pettersson, M., 55
Pettibone, D. J., 1169
Pfaus, J. G., 309
Phelps, C. J., 1127
Pierzchala, K., 1035
Pontiroli, A. E., 455
Porreca, F., 625
Powell, R. C., 185
Prasad, C., 327, 569
Preussler, D. W., 493
Price, D. A., 515, 533
Primi, M. P., 619
Princen, M. M., 1057
Puglisi-Allegra, S., 935

Quillfeldt, J., 605
Quiroz, A. C., 609
Quito, F. L., 1029

Racz, K., 461
Radil, T., 785
Rajakumar, G., 855, 997
Rao, J. K., 327, 569
Rayford, P. L., 1061
Read, D., 961
Rice, J. C., 609
Rice, K. C., 1015
Riehm, J. P., 515
Riekkinen, P., 261
Riemen, M. W., 877
Rioux, F., 863, 1079
Ritter, S., 677
Rivier, J., 1011
Rodriguez, M., 1023
Rodriguez-Sierra, J. F., 539
Rogers, R. C., 505
Romita, V. V., 213
Roos, B. A., 207
Rorstad, O. P., 477, 663, 849
Roselli, C. E., 159
Ross, G. M., 989
Rothenberg, M. E., 1119
Rothman, R. B., 645, 1015
Rozé, C., 89, 1023

Saavedra, J. M., 737
Saegesser, B., 599
Sahu, A., 921
Saint-Pierre, S., 61
Sakatani, N., 651
Sakurai, H., 285
Salzman, S. K., 247
Samson, W. K., 449
Sander, G. E., 609
Sarles, H., 967
Sasaki, Y., 119
Satoh, M., 905
Schally, A. V., 951
Scheving, L. A., 347
Scheving, L. E., 347
Schiffmann, S., 1107
Schoenenberger, G. A., 599, 773
Seeburg, P. H., 335
Seger, M. A., 757
Seidah, N. G., 593
Sennef, C., 261
Shaffer, M. M., 1101
Shibuya, H., 355
Shizume, K., 285
Shulkes, A., 961
Shuster, S., 955
Sica, F., 791
Siegel, S. F., 811
Silva, A., 983
Simard, J., 199
Singer, M. V., 973
Škopková, J., 785
Sleeman, M., 223
Smith, A. I., 1045
Smith, G. C., 223
Smith, G. P., 127, 845
Smith, T. L., 467
Smitz, S., 261
Snider, R. H., 977
Sobocinska, J., 1003
Soininen, H., 261
Song, T., 335
Sourkes, T. L., 437
Spampinato, S., 695, 709
Spencer, S. E., 887
Speth, R. C., 677
Spies, H. G., 159
Sroczynska, I., 431
Stadil, F., 639
Stanley, B. G., 237
Stein, R. B., 877
Steinman, J. L., 585
Stepien, H., 951
Stock, S., 411
St-Pierre, S., 863, 1079
Strimas, J. H., 1165
Strohmayer, A. J., 845
Su, M. C., 769
Suemaru, S., 113
Sugawara, M., 113
Suh, H. H., 123
Sun, D. H., 473
Suzuki, Y., 663
Szczepanska-Sadowska, E., 1003

Tabassian, A. R., 977
Taché, Y., 1011
Takagi, H., 905
Takahashi, H., 1075
Takao, T., 113
Takashima, M., 355
Talman, W. T., 887
Tanaka, H., 169, 257
Tanini, A., 893
Tatemoto, K., 921
Terenius, L., 371
Theodorsson-Norheim, E., 13
Thibault, G., 461
Thody, A. J., 955
Tiberi, M., 947
Tinius, T. P., 493
Toccafondi, R., 893
Todt, J. A., 747
Tonon, M.-C., 69, 1093
Törnebrandt, K., 251
Totaro, J. A., 1169
Trout, W. E., 367
Tsai, T. H., 347
Tseng, L.-F., 123
Tsuchiya, M., 391
Tsugu, M., 391
Tsujii, S., 1075
Tsukada, N., 391
Tsutsumi, Y., 77

Uchimura, H., 49
Ueda, H., 905
U'Prichard, D. C., 543
Usui, T., 1075
Uvnäs-Moberg, K., 411

Vagne, M., 423
Vanderhaeghen, J.-J., 911, 1107

Vandesande, F., 135
Van Dijk, A., 773
van Loenhout, H., 515
Van Loon, G. R., 1035
Van Reeth, O., 1107
Vargas, M. A., 291
Vargo, E. B., 207
Varro, A., 95
Vaudry, H., 61, 69, 1093, 1107
Veale, W. L., 385
Ventura, C., 695, 709
Verburg-Van Kemenade, B. M. L., 61, 69, 1093
Verhaagen, J., 581
Verstappen, A., 1107
Vincent, J. P., 195
Visser, T. J., 69
Wagner, G., 797
Walker, J. M., 701, 811, 837, 869
Wang, Y.-N., 145
Wasterlain, C. G., 585
Watanabe, K., 77
Watson, S., 523
Wegrzyn, R. J., 877
Wei, E. T., 1051
Weiss, K. R., 179
Welches, W. R., 939
Welton, M., 1011
Wen, H. L., 191
Wendt, R. L., 747
Wiesenfeld-Hallin, Z., 153
Wilber, J. F., 543
Willis, G. L., 223
Wilson, I. B., 21
Winokur, A., 247
Wire, W. S., 613
Wooledge, K., 721
Wyatt, R. J., 145
Wypij, D. M., 21

Xu, C., 769
Xue, D., 769

Yachabach, T. L., 841
Yalow, R. S., 165
Yamamura, H. I., 613
Yamashita, Y., 639
Yanaihara, C., 575
Yanaihara, N., 77, 575
Yang, C. L., 769
Yang, H.-Y. T., 657
Yashpal, K., 213
Yirmiya, R., 763
Yoder, D. G., 103
Yokoo, H., 49
Yonei, Y., 391
Young, E. A., 701, 811
Yu, K. L., 855

Zagari, A., 791
Zahniser, D., 721
Zelazowski, P., 951
Zhou, Z.-C., 633